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their fellow men. I go back 2,500 years and how many can I count in that period? I can count 
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Contexte et état de l’art 
 
Les microparticules, aussi appelées microvésicules, sont des fragments de la 
membrane plasmique émis en réponse à un stress cellulaire et retrouvées dans les fluides 
biologiques tels que le sang, l’urine, le liquide céphalo-rachidien, les larmes, les crachats ou 
les liquides bronchoalvéolaires.  
 
Dans le sang, les microparticules (MPs) circulantes sont des marqueurs de l’activation ou de 
l’atteinte cellulaire et également des effecteurs capables de disséminer un message biologique 
à des cellules endothéliales ou vasculaires à distance de la cellule émettrice.  
 
Ces dernières années, le laboratoire ainsi que d’autre équipes nationales et 
internationales a démontré que des concentrations élevées de MPs circulantes témoignent de 
la sévérité de la maladie qu’elle soit chronique ou aigue. (Ridger, Boulanger et al. 2017) De 
plus l’origine cellulaire elle-même de ces MPs varie avec l’évolution de la maladie comme 
par exemple dans le choc septique dans lequel les MPs d’origine endothéliale sont indicatives 
d’une évolution vers la coagulopathie, également associée à la présence de MPs d’origine 
neutrophilique. (Delabranche, Quenot et al. 2016, Delabranche, Stiel et al. 2017) 
Dans le sang périphérique, les MPs circulantes sont majoritairement d’origine plaquettaire, 
leucocytaire, endothéliale ou érythrocytaire. Cependant, d’autres MPs émises par des organes 
hautement vascularisés sont détectables dans le flux sanguin périphérique, notamment en 
situation de stress cellulaire majeur, comme au cours de l’ischémie-reperfusion ou lors d’un 
remodelage tissulaire important de l’organe. (Bakouboula, Morel et al. 2012) (Bakouboula, 
Morel et al. 2008, Bal, Ederhy et al. 2010) Ainsi des MPs de cellules hépatocytaires sont 
détectées par exemple dans la stéatose alcoolique ou des MPs cellules  béta du pancréas chez 
les patients diabétiques de type 1 en rejet de greffe d’îlots pancréatiques. (Toti, Bayle et al. 
2011, Moreau, Toti et al. 2012, Rautou, Vion et al. 2013, Lemoinne, Thabut et al. 2014). 
 
Du fait de leurs propriétés procoagulantes et proinflammatoires, les MPs ont été 
longtemps étudiées comme des effecteurs endothéliaux capables d’amplifier la réponse 
inflammatoire endothéliale et procoagulante, de favoriser la formation du thrombus voire la 
constitution de plaques d’athéromes. Ainsi, les MPs d’origine leucocytaires sont associées au 
risque primaire et secondaire d’athérothrombose. (Koga, Sugiyama et al. 2005, Chironi, 
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Simon et al. 2006) En effet, les MPs leucocytaires et plaquettaires portent des molécules 
actives et sont capables d’interagir avec les cellules et avec les MPs par interactions contre-
récepteurs ligands notamment via les protéines d’adhésion, ou via Fas/ Fas ligand, ou même 
par fusion lipidique.  
 
Les propriétés procoagulantes des MPs sont dues à la phosphatidylsérine un 
aminophospholipide anionique (Pser) et au facteur tissulaire (FT) initiateur cellulaire de la 
coagulation inductible dans les cellules endothéliales, monocytaires et neutrophilique 
principalement. La Pser est séquestrée dans le feuillet interne de la membrane plasmique au 
repos et transloquée dans le feuillet externe en réponse à l’influx calcique concomitant à la 
stimulation. Ainsi, la Pser constitue une surface anionique capable de focaliser les facteurs de 
la coagulation et leur assemblage, nécessaire à la production de l’enzyme ultime de la 
cascade : la thrombine qui clive le fibrinogène en fibrine constituant ainsi un maillage 
stabilisant le caillot ou le thrombus. Plus récemment la fonction hémostatique des MPs a été 
mise en évidence par le biais du syndrome de Scott, un syndrome hémorragique caractérisé 
par une incapacité de la membrane plasmique des plaquettes, érythrocytes et lymphocytes à 
émettre des MPs procoagulantes en réponse à une stimulation aigue, c’est à dire en situation 
de blessure vasculaire provoquée. (Toti and Freyssinet 2005, Lhermusier, Chap et al. 2011) 
D’autres données cliniques ou dans des modèles animaux indiquent que le risque 
hémorragique est aggravé en cas de cytopénie  et de concentration faible de MPs circulantes. 
Ainsi, les MPs circulantes peuvent être considérées comme une surface additionnelle pour 
l’assemblage des complexes de la coagulation en situation de réponse hémostatique. Il est 
intéressant de noter que les MPs d’origine endothéliale et leucocytaire ont donc un double 
pouvoir procoagulant porté par la Pser et le FT.   
 
La translocation de la Pser en réponse à l’activation cellulaire est le résultat de (i) 
l’inhibition des flippases qui au repos rapatrient toute Pser du feuillet externe vers le feuillet 
interne de la bicouche lipidique, et à  (ii) l’activation des floppases responsables du transport 
inverse sous l’effet de l’influx calcique et des scramblases, brasseurs de phospholipides non 
spécifiques. Une floppase a récemment été identifiée grâce à l’identification de mutations 
dans le gène de l’anoctamine 6 (TMEM16F), chez les patients atteints du syndrome de Scott. 
(Toti and Freyssinet 2005)  Cependant, les modalités d’action des différentes floppases restent 
mal connues, notamment en raison de transporteurs qui sont des floppases occasionnelles 
comme les transporteurs ABCA-1, MDR-1, MDR-2, et du fait d’un défaut d’outil 
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pharmacologiques réellement spécifiques de chaque transporteur. (Ridger, Boulanger et al. 
2017).   
 
Dans le contexte général des maladies associées aux désordres cardiovasculaires, les 
concentrations circulantes de MPs d’origine endothéliale sont généralement élevées comme 
dans le diabète, l’infarctus du myocarde, et l’hypertension artérielle pulmonaire.(Omoto, 
Nomura et al. 2002, Morel, Hugel et al. 2004, Davi and Ferroni 2005, Koga, Sugiyama et al. 
2005, Koga, Sugiyama et al. 2006, Feng, Chen et al. 2010, Diehl, Aleker et al. 2011, 
Boulanger, Loyer et al. 2017) Plus récemment, le laboratoire a montré que les MPs émises par 
des cellules endothéliales de coronaires de porc induites en sénescence réplicative étaient des 
effecteurs pro-sénescents induisant un arrêt prématuré du cycle cellulaire. De plus, des MPs 
endothéliales pro-sénescentes circulaient chez les patients à risque cardiovasculaire élevé. Les 
propriétés pro-sénescentes des MPs endothéliales sont associées à une activation précoce et 
redox-sensible des MAP-kinases et de la PI-3kinase. (Abbas, Jesel et al. 2017) Ces résultats 
sont cohérents avec l’observation d’une atteinte de la fonction vasculaire endothélium-
dépendante décrite dans les modèles animaux chez qui la sénescence endothéliale est détectée 
précocement aux bifurcations vasculaires prédisposant à la dysfonction endothéliale, comme 
la crosse aortique. (Sonia Khemais, Thèse de l’Université de Strasbourg 2017). 
 
 Le vieillissement est associé à une modification de l’ensemble du système immunitaire 
touchant tous les organes de l’immunité et affectant la production de lymphocytes B et T 
matures. On constate une perte progressive de leur fonction associée à la sénescence de 
certains sous-types et l’apparition de tumeurs et de maladies auto-immunes. Le rôle et 
l’importance des MPs émises par les cellules leucocytaires dans un contexte de sénescence 
cellulaire reste peu exploré, notamment en raison de la difficulté à obtenir des quantités 
suffisantes de MPs issues de cellules primaires. En effet, chez le petit animal les volumes 
sanguins ne sont pas suffisants pour autoriser des études de modèles de communication 
intercellulaire. Les MPs de cellules leucocytaires émises en conditions de stress cytokinique à 
partir de lignées immortalisées sont connues pour leurs propriétés pro-inflammatoires vis à vis 
de l’endothélium. Ainsi les MPs de cellules monocytaires constituent une voie majeure de 
sécrétion d’IL-1ß active tandis que les MPs lymphocytaires convoient Fas et Fas ligand. 
(Albanese, Meterissian et al. 1998, MacKenzie, Wilson et al. 2001). 
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Le laboratoire a également mis en évidence dans un modèle de communication 
intercellulaire induite par les MPs, que les MPs leucocytaires issues de la rate des rats étaient 
capables de déclencher une réponse pro-sénescente des cellules endothéliales coronaires sans 
initier d’apoptose, suggérant un effet spécifique. (Thèse Ali El Habhab, Université de 
Strasbourg, 2018). Par ailleurs, ces MPs splénocytaires sont majoritairement émises par des 
cellules de l’immunité innée ou adaptative (lymhocytes B, lymphocytes T, neutrophiles, 
monocytes, plaquettes) 
 
Dans le contexte plus particulier du diabète, l’équipe a  établi que les cellules béta 
sécrétrices d’insuline sont capables d’émettre des MPs porteuses de FT en réponse à un 
stimulus cytokininique. Ces MPs se comportent comme des effecteurs pro-inflammatoires et 
proapoptotiques et agissent au moins partiellement par des voies de signalisation dépendantes 
du récepteur GLP-1. (Gleizes, Constantinescu et al. 2014, Gleizes, Kreutter et al. 2016) Enfin, 
S. Khemais a établi au laboratoire que la sénescence des cellules endothéliales de coronaires 
était induite prématurément au bout de 4 jours en présence de forte concentrations de glucose 
(25 mM) et que les voies de signalisation impliquées sont redox-sensibles. (Khemais-
Benkhiat, Abbas et al. 2016) 
 
Il est important de noter que les cellules endothéliales en sénescence prématurée sont 
dysfonctionnelles et présentent un phénotype particulier pro-inflammatoire et procoagulant, 
que ce soit en réponse au glucose élevé ou en réponse aux MPs pro-sénescentes d’origine 
endothéliale ou leucocytaire.  
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Hypothèses et objectifs 
 
L’ensemble de ces données ont conduit aux hypothèses suivantes:   
- les MPs émises par les leucocytes contribuent à la sénescence endothéliale et au 
vieillissement prématuré du vaisseau 
- Au cours du diabète, l’émission soutenue de MPs d’origine leucocytaire contribue à la 
sénescence prématurée de l’endothélium  
- La protection pharmacologique de l’endothélium contre la sénescence prématurée 
induite par les MPs est une cible intéressante pour la protection vasculaire au cours du 
diabète  
  
Pour explorer ces hypothèses nos objectifs ont été  
- De valider une approche méthodologique pour l’isolement des MPs tissulaires en 
utilisant la rate comme source de MPs leucocytaires, les artères coronaires porcines 
comme source de MPs du tissus vasculaire  
- D’étudier l’effet de l’âge et du glucose à forte concentration sur l’émission des MPs 
tissulaires  
- De caractériser les propriétés pro-sénescentes des MPs isolées de la rate sur 
l’endothélium coronaire dans un modèle de sénescence induite par le glucose. 
- D’établir l’effet de ces MPs sur la réponse vasculaire dépendante de l’endothélium, 
notamment dans des conditions de stress glucosé. 
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Résultats 
 
 
I- Approche méthodologique pour l’étude des MPs tissulaires : 
Nous avons choisi d’utiliser les cellules de rate du rat comme source de cellules 
immunes. L’avantage de cette méthode est la possibilité d’étudier des MPs d’animaux traités 
par des agents pharmacologiques. Le procédé est basé sur l’isolement de splénocytes après 
choc osmotique et leur conservation en milieu de culture avant une éventuelle stimulation par 
du LPS ou une combinaison de PMA/ionophore A23187 afin d’étudier les capacités des 
cellules à émettre des MPs en condition de stress. Les MPs sont ensuite isolées par des étapes 
de centrifugation différentielle afin d’obtenir une suspension de MPs concentrées et lavées 
issues de cellules non stimulées (SMPCTL) ou stimulées par les agonistes (SMPLPS , SMPPMA/I)  
Pour valider la fiabilité de la méthode d’extraction, nous avons comparé les 
concentrations et les propriétés des MPs émises à l’état basal par les splénocytes de rats 
jeunes, d’âge moyen et vieux après 24h de mise en culture. Les MPs ont ét mesurées soit par 
dosage prothrombinase, soit par dosage de leur contenu protéique. Les propriétés pro-
sénescentes des MPs isolées ont été évaluées après application 48h à des cellules 
endothéliales (ECs) de coronaires de porc dans un modèle cellulaire visant à se rapprocher des 
conditions des premières lésions athéro-thrombotiques.  
Les données montrent que la concentration de MPs émises à l’état basal (sans 
stimulation des splénocytes) augmente significativement avec l’âge et que la sénescence 
endothéliale mesurée par l’activité de la galactosidase spécifique de la sénescence (SA-ß 
galactosidase) est induite de manière significativement supérieure par les MPs de rats d’âge 
moyen et de rats âgés comparativement aux rats jeunes. Ainsi, les propriétés pro-sénescentes 
des MPs splénocytaires augmentent avec l’âge du rat et les splénocytes eux-mêmes ont une 
capacité à émettre des MPs qui augmente avec l’âge, ce dernier favorise aussi la production 
de MPs en réponse au PMA/I ou au LPS (PMA /I : 2.32 fois vs. 1.57 fois splénocytes de rats 
d’âge moyen vs. Rats âgés).  
La cinétique d’émission des MPs semble être un événement très précoce que ce 
soit par les splénocytes ou par les anneaux d’artères coronaires. En effet après 1h, les MPs 
sont détectables et les concentrations élevées de glucose augmentent significativement leur 
émission (30 % après 90 min pour les MPs splénocytaires et 25 % après 50 min pour les 
anneaux d’artères).   
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En conclusion, la méthode d’extraction des MPs de la rate et des vaisseaux est fiable et 
reproductible. Quelle que soit la source tissulaire, les MPs sont procoagulantes (dosage 
prothrombinase) et la méthode conserve les propriétés effectrices des MPs qui reflètent l’état 
physiopathologique (pas d’effet pro-sénescent des MP de rat jeune), ou l’environnement du 
tissu (forte teneur en glucose). L’identification des mécanismes en jeu dans l’émission des 
MPs reste à réaliser dans les deux modèles avant d’envisager un conrtôle pharmacologique. 
La rate est une source importante de MPs chez les petits animaux.  
 
II- Les concentrations élevées de glucose (« high Glucose, HG ») potentialisent 
l’effet pro-sénescent des MPs leucocytaires sur l’endothélium coronaire et sur 
le tonus vasculaire. 
 
 
L’effet pro-sénescent et pro-inflammatoire des MPs splénocytaires SMPLPS, SMPPMA/I, 
SMPCTL a été mesuré dans un modèle de sénescence endothéliale coronaireinduite par le 
glucose (25 mM appliqué pendant 96h).  
Après 48h de traitement par le glucose, l’addition de SMPLPS, SMPPMA/I, double l’effet 
pro-sénescent du glucose mesuré par l’activité SA-ß galactosidase dans les cellules d’artères 
coronaires de porc. Les western blots indiquent que le HG potentialise la surexpression des 
marqueurs pro-sénescents p-16 et p21 induites par les SMPLPS, SMPPMA/I mais pas aux 
SMPCTL. Par ailleurs, si SMPLPS, SMPPMA/I induisent un baisse modérée de l’expression de la 
eNOS et une surexpression modeste des protéines pro-inflammatoires COX-2, ICAM-1, 
VCAM-1, une synergie est également observée en présence de HG qui double voir triple la 
réponse induite par les SMPLPS, SMPPMA/I alors que la réponse aux SMPCTL n’augmente au 
plus que de 50 %, en présence de HG.  
Pour confirmer la dysfonction endothéliale consécutive à la sénescence, et parce que 
les COX-2 sont susceptibles d’intervenir dans la réponse EDCF, les SMPs ont été appliquées 
à des anneaux d’artères coronaires de porc à différentes concentrations et en présence de 
milieu normoglucosé (NG) ou HG. Après 18h d’incubation (37 °C), la relaxation 
endothéliale-dépendante a été mesurée en réponse à la bradykinine. Les résultats indiquent 
que les SMPCTL n’ont aucun effet sur le tonus vasomoteur mais que les SMPLPS, SMPPMA/I 
réduisent la relaxation induite par la bradykinine en milieu NG et que le HG amplifie cet effet, 
alors que seul il n’altère pas la réponse après 18h d’incubation. L’impact endothélial a été 
confirmé par analyse immuno-histochimique des anneaux de coronaires qui montre une 
accumulation des ROS induite par les SMPLPS, SMPPMA/I uniquement et qui est augmentée en 
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présence de HG. Au contraire, le HG diminue l’expression de la eNOS de manière drastique 
en présence de SMPLPS, SMPPMA/I. Alors que le HG seul augemente modérémment 
l’expression endothéliale de COX-2, ICAM-1 et VCAM-1 dans la monocouche endothéliale 
des anneaux, le HG potentialise drastiquement leur effet (multiplié par un facteur 2 ou 4). 
 
En conclusion, les MPs de splénocytes stimulés par LPS ou PMA/I mais pas celles de cellules 
naives non stimulées sont des effecteurs endothéliaux pro-sénescents, pro-inflammatoires et 
pro-oxydants. L’effet optimum a été caractérisé après 48h d’exposition dans un modèle de 
cellules endothéliales primaires de coronaires de porc isolées, mais aussi dans un modèle d’ 
anneaux d’artères coronaires de porc. Ces MPs conduisent à une dysfonction endothéliale 
caractérisée par à une capacité de relaxation dépendante de l’endothélium moindre après une 
exposition prolongée (18h). Les mécanismes restent à identifier.   
 
III- Protection pharmacologique de l’endothélium contre les SMPs prosénescentes 
et la potentialisation de leurs effets par le glucose. 
 
Parce que de fortes concentrations en glucose (HG) favorisent l’apparition d’une sénescence 
endothéliale dans les cellules endothéliales d’artères coronaires de porc ainsi que l’apparition 
d’un phénotype endothélial pro-inflammatoire et procoagulant, nous avons cherché à évaluer 
la réponse endothéliale-dépendante d’anneaux d’artères coronaires après incubation en 
présence de HG. S. Khemais a montré dans sa thèse que les transporteurs SGLT (Sodium 
Glucose transporters) sont impliqués dans la sénescence endothéliale induite par les fortes 
concentrations de glucose (HG, 25 mM).  Dans notre série d’expériences, l’exposition 
prolongée au HG pendant 18h en présence d’inhibiteurs des transporteurs SGLT a indiqué 
que le HG diminue la réponse contractile à l’activateur U46619l et que les inhibiteurs des 
SGLT1 ou de SGLT2 abolissent complètement l’inhibition de façon endothéliale-dépendante 
aucune protection en absence d’endothélium). De plus, l’utilisation d’inhibiteurs 
pharmacologiques ajoutés 15 minutes avant la mesure indique que l’effet n’est pas dépendant 
des COX ou des ROS mais implique les canaux potassium dépendants SKa et IKa. Dans le 
tissu artériel, l’analyse des anneaux après 18h d’incubation montre que la concentration en 
glucose favorise l’accumulation des ROS dans le tissu et la surexpression des COX-2, de 
VCAM-1, ICAM-1 et la répression de l’expression de la eNOS dans la couche endothéliale de 
manière SGLT1 et 2 dépendante.  
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L’ensemble de ces données indique que la perte de vasocontraction dans les vaisseaux après 
24h d’exposition prolongée à une forte concentration de glucose est dépendante des 
transporteurs SGLTs. L’analyse histologique suggère un mécanisme redox-sensible qui 
implique tout le tissu pariétal  et la mesure des MPs émises par l’anneau aortique après moins 
de 2h suggère une action très précoce des inhibiteurs de SGLTs qui limitent également la 
production de MPs vasculaires endogènes (cf. paragraphe précédent). Les résultats devront 
être complétés par l’analyse d’autres marqueurs d’activation du tissu pariétal comme les 
récepteurs de l’angiotensine, l’enzyme de conversion de l’angiotensinogène ou le facteur 
tissulaire, tous impliqués dans la réponse athérothrombogénique du vaisseau et plus 
particulièrement de l’endothélium. 
 
Conclusion générale 
 
Ce travail démontre que l’étude des MPs tissulaires à partir d’organes est une bonne 
alternative à la mesure des MPs circulantes, particulièrement lorsque l’animal est de petite 
taille. Notre méthode d’extraction est suffisamment douce pour conserver les propriétés de 
biomarqueurs des MPs. Ainsi, Les MPs extraites de rate ont des propriétés différentes selon 
l’état physiopathologique ou le traitement du rat.  
Nos mesures par différentes méthodes (dosage protéique ou dosage prothombinase), indiquent 
que l’âge ou la concentration en glucose modifient le degré d’émission des MPs par les tissus 
et cela de façon très précoce, mais aussi les propriétés pro-sénescentes et pro-indlammatoires 
des MPs examinées dans un modèle de sénescence endothéliale à partir de cellules primaires 
d’artères coronaires de porc ou directement par analyse histochimique d’anneaux d’artères 
coronaires. Enfin, dans notre modèle, seules les MPs émises en réponse à un stress induisent 
une dysfonction endothéliale, ce qui suggère également que les MPs leucocytaires sont une 
cible pharmacologique d’intérêt dans les maladies chroniques qui favorisent une activation 
cellulaire soutenue. Dans ce cadre, la contribution des transporteurs SGLT1/2 dans la réponse 
à long terme de l’endothélium inflammatoire au glucose reste à confirmer, notamment par la 
recherche de l’expression des miRNA et des proteines dans les tissus et cellules. Nos résultats 
suggèrent qu’une des stratégies thérapeutiques éventuelles serait de limiter la sénescence 
endothéliale et la libération de MPs endothéliales pro-sénescentes secondaires.     
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Introduction  
 
 Humans and other mammals live numerous relationships with pathogenic and non-
pathogenic microorganisms that may debilitate or contribute to ordinary homeostasis. The 
immune system continuously accommodates to protect the host, through early innate and late 
adaptive immune systems that incorporate self-non self discrimination to recognize and 
eventually eliminate pathogenic organisms.  
The vessel is the route for immune cells of the innate response to target microorganisms at 
site of infection.  However, immune responses are also the support of immunothrombosis that 
are deleterious to vascular health and may favour excessive inflammatory responses of the 
endothelium leading to a prothrombotic endothelial phenotype.  
Numerous studies have shown that endothelium dysfunction associated with loss of 
endothelial vasoprotective properties, is one of the major factors contributing to vascular 
disease in the elderly and in chronic diseases with cardiovascular and thrombotic disorders 
such as diabetes. Recently, it has been suggested that endothelial senescence progressively 
occurring with aging may contribute to the endothelial dysfunction. 
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Chapter One 
Overview of the immune system and of its 
responses to E. coli lipopolysaccharide  
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I-1 The spleen 
The spleen is the largest filter in the body of blood, located in the abdomen and 
connected to the stomach (Kraal 1992, Steiniger and Barth 2000).. Figure (1). The spleen 
combines the cells of innate and adaptive immune system and also enables removal of the old 
erythrocytes from the bloodstream. This function, in combination with a highly regulated 
lymphocyte responses and proliferation, makes of the spleen the most important organ for 
antibacterial and antifungal immune interactions (Mebius and Kraal 2005) and leads to the 
effective removal of microorganisms transmitted by blood and cellular debris. 
 
 
Figure 1: Structure of the spleen (Mebius and Kraal 2005) The spleen is organized 
in regions called the red pulp and white pulp, which are separated by an interface 
called the marginal zone (MZ) (MacNeal 1929) 
 
I-1.1 Immune cells and leukocytes in the spleen: 
 Immune cells in the spleen include different subsets of T and B cells, dendritic cells 
(DCs) and macrophages. The macrophages of the red pulp are specialized in phagocytosis of 
aging red blood cells and regulate iron recycling and release. MZ Macrophages of the 
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marginal zone (MZ) and metallophilic macrophages express a unique set of pattern-
recognition receptors and contribute to the removal of blood bacteria and viruses. Also, the 
MZ contains MZ B cells and dendritic cells (DCs) (Mebius and Kraal 2005). The spleen 
contains all major types of mononuclear phagocytes, including macrophages, DCs and 
monocytes. These cells identify pathogens and cellular stress, regulate tissue homeostasis and 
inflammatory responses, remove dead cells and foreign material, and shape adaptive 
immunity (Bronte and Pittet 2013). In addition to DCs and macrophages, natural killer T 
(NKT) cells of the spleen, which sense lipid antigens secrete cytokines and induce 
downstream activation of adaptive immune cell types (Barral, Sanchez-Nino et al. 2012), see 
figure 1. 
 
I-2 Overview of the Immune Response 
 Immune responses rely on self-non self-discrimination to respond to invading 
microbes and other exogenous threats and can be divided in innate immune system and 
adaptive immune systems (Chaplin 2010). 
 
I-2.1 The innate immune system 
The innate immune response is essential for barrier against microbial pathogens. The 
innate immune system involves all aspects of host immune defense mechanisms including 
physical barriers, such as epithelial cell layers, the epithelial cilia, and the secreted mucus 
layer that overlays the epithelium. Another local barrier is obtained through the recruitment of 
neutrophils that shed neutrophil extracellular Traps (Nets) that constitute at site of bacterial 
infection a network of decondensed chromatin also carrying oxidases and proteases. The 
innate response also requires soluble proteins and bioactive small molecules that are either 
primarily present in biological liquids (such as the defensins and complement proteins) or 
which are released from cells as they are activated. Among them chemokines that attract 
inflammatory leukocytes, lipid mediators of inflammation, enzymes and bioactive amines that 
participate to tissue inflammation, cytokines that act as autocrine or paracrine cell effectors, 
and reactive free radical species. Finally, the innate immune system relies on membrane 
receptors that bind the molecular patterns expressed by microbial surfaces (Chaplin 2010). 
 There is a noticeable comparable pattern of gene expression in human peripheral blood  
mononuclear cells caused by bacterial lipid polysaccharides and killed bacteria although some 
 16 
differences were observed according to each type of bacteria, most probably linked to 
discrepancies in bacterial virulence (Boldrick, Alizadeh et al. 2002).  
 
I-2.2 The Adaptive immune system  
The adaptive immune response relies on T cells and B lymphocyte cells (Medzhitov 
and Janeway 2000). Adaptive responses are basically based on specific antigen receptors 
expressed on the surfaces of T- and B-lymphocytes. The antigen-specific receptors of the 
adaptive response are encoded by the genes sorted by somatic rearrangement of germ-line 
gene elements to form T cell receptor and B cell receptor (Chaplin 2010). 
 
I-3 Escherichia coli  
I-3.1 Structure & Classification  
 Escherichia coli (E. coli) is one of the most common inhabitants of the human 
intestinal tract and considered to be an indicator of the quality of water and food contaminated 
with faeces.  
E. coli is the predominant facultative anaerobic bacteria. The organism usually colonizes the 
infant's digestive system within hours of life, and then, E. coli and the host derive mutual 
benefit. 
E. coli is the canonical specie from genus Escherichia within the family Enterobacteriaceae. 
Phylogenetic analyses have shown that E. coli strains fall into four main phylogenetic groups 
(Selander, Caugant et al. 1986, Herzer, Inouye et al. 1990) and that virulent extra-intestinal 
strains belong to group B2 and, to a lesser extent, to group D (Bingen, Picard et al. 1998, 
Boyd and Hartl 1998, Picard, Garcia et al. 1999, Johnson and Stell 2000), and can be divided 
into seven subgroups (A0, A1, B1, B22, B23, D1 and D2) according to the combination of the 
genetic markers (Escobar-Paramo, Le Menac'h et al. 2006). 
Table 1: E. coli phylogenetic classification 
Domain Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Order Enterobacteriales 
Family  Enterobacteriacae 
Genus Escherichia 
Species coli 
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E. coli can be recovered easily from clinical specimens on general or selective media under 
aerobic conditions at 37°C. E. coli in stool are most often recovered on MacConkey or eosin 
methylene-blue agar, which selectively grow members of the Enterobacteriaceae and allows 
differentiation of enteric organisms depending on the morphology. About 90% of E. coli 
strains are lactose positive whereas its 99% of E. coli strains are positive with indole test 
which is the single best test for differentiation from other members of the 
Enterobacteriaceae (Balows and Shadomy 1991).  
 
I-3.2 E. Coli as a pathogen  
 Adam, in 1927, suspected that certain strains of E. coli were the cause of infantile 
diarrhea and identified several by a series of fermentation and biochemical tests (Adam 1927). 
Then Goldschmidt, Cooper and coll. isolated the strains from babies with diarrhea 
(Goldschmidt 1933, Cooper 1955). E. coli is a leading reason of infant diarrhea, killing 
hundreds of thousands of children annually worldwide (DeVinney, Gauthier et al. 1999, 
Anselmi, Toti et al. 2017). Various E. coli strains cause a wide range of extra-intestinal 
diseases, such as urinary tract infections, neonatal meningitis, diarrhea, septicaemia (Drasar 
1974, Orskov and Orskov 1992), and some strains contain endotoxins that cause traveler's 
diarrhea and very. The term endotoxins refers to toxic materials, secreted toxins being known 
as ‘‘exotoxins” (Wang and Quinn 2010).  
 
I-3-3 Lipopolysaccharide of E. coli 
 The outer membrane of E. coli is composed of two lipid monolayers, the inner 
consisting primarily of glycerophospholipids and similar in lipid composition to the two 
monolayers of the inner membrane. In contrast, lipopolysaccharide (LPS) is the major 
component of the outer monolayer of the outer membrane. (Figure 2) 
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Figure 2: Structure of bacterial cell walls. Only Gram-negative bacteria have an outer 
membrane that contains lipopolysaccharides (LPS)(Turner, Healey et al. 2012) 
 
 
I-3.3.1 Structure of lipopolysaccharide of E. coli 
The LPS of E. coli is composed of three parts: lipid A, Core oligosaccharides, and O-
antigen replicate (Figure 3).  
Lipid A is a hydrophobic component of the LPS which is located in the outer leaf of the outer 
membrane, while core polysaccharides and O-antigen replicate on the surface of the bacterial 
cells (Holst 1999, Raetz and Whitfield 2002, Raetz, Reynolds et al. 2007). The core-lipid A 
and the O-antigen are synthesized at the cytoplasmic surface of the inner membrane, and then 
assembled in the periplasm to produce LPS molecules further exported across the inner 
membrane to the outer leaflet of outer membranes (Doerrler 2006). 
   The O-antigen consists of repeating oligosaccharide units (O units) each containing three to 
five or more monosaccharide residues such as glucose, galactose, mannose, rhamnose, fucose, 
and, rarely, dideoxyhexoses such as abequose, tyvelose, paratose, or colitose. O-antigen is 
synthesized by assembly of monosaccharide residues by glycosyltransferase. The O-antigens 
of LPS exhibit considerable diversity and is formed of homopolymers or heteropolymers. The 
connection of units in O-antigen may be branched or linear. In E. coli, the numbers of O-
antigen groups are 164 (Wang and Quinn 2010). 
   Core oligosaccharides contribute to two distinct structures: the outer core of the O-antigen 
repeats and the inner core bound to lipid A. The structures of core oligosaccharides differ with 
E. coli strains R1, R2, R3, R4, and K-12, (Muller-Loennies, Lindner et al. 2002, Muller-
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Loennies, Lindner et al. 2003) with some common core oligosaccharides that are keto-
deoxyoctulosonate, heptose, D-galactose and D-glucose (Wang and Quinn 2010). Figure (3) 
Lipid A is the bioactive part of LPS and in E. coli it is a strong stimulator of the innate 
immune system (Golenbock, Hampton et al. 1991). 
 
I-3.3.2 Response of the immune cells to LPS: PAMPS and PRRs 
The innate immune system is the first line of host defense against pathogens that leads 
to a proinflammatory response. The innate immune response can differentiate self and the 
pathogens by pattern recognition receptors (PRRs). PRRs have common properties, first, 
PRRs can identify pathogen-associated molecular patterns (PAMPs), that are fundamental for 
the microorganism, therefore, difficult for the microorganism to alter at any stage of their life-
cycle. The different innate immune cells of host organisms such as monocytes, macrophages, 
neutrophils and stem cells can identify LPS bound to a specific receptor exposed at their 
surfaces called toll-like receptor 4 (TLR4) (Poltorak, He et al. 1998, Medzhitov and Janeway 
2000, Akira, Uematsu et al. 2006) (see below). Lipid A seems the portion of LPS mainly 
responsible for TLR4-mediated immune responses. The number and length of fatty acyl 
chains and the phosphate groups of lipid A determines the affinity for TLR4 (Loppnow, 
Brade et al. 1989, Rietschel, Kirikae et al. 1994) and its virulence (Montminy, Khan et al. 
2006) 
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Figure 3: A: Structure and biosynthesis of LPS in E. coli. For each reaction the substrate 
(blue) is converted by a specific enzyme (red). The structure of lipid A is shown in details, but 
structures of core oligosaccharides and O-antigen are simplified as symbols since there are 
many variations in these two regions (Raetz and Whitfield 2002, Raetz, Reynolds et al. 2007) 
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Figure 3B: Structure of LPS in E. coli (Raetz and Whitfield 2002, Raetz, Reynolds et al. 
2007) 
 
I-3.3.3 Bacterial virulence, LPS, severity of the disease and impact on therapy 
Virulence is the ability of bacteria to infect the host and cause disease. It is 
characterized in terms of the number of infecting bacteria, the route of entry, the effects of 
host defense mechanisms, and intrinsic characteristics of the bacteria called virulence factors.  
In fact, the structure of LPS that varies from one bacterium to another, could itself affect the 
bacterial virulence (Wilkinson 1996). Since LPS is the first molecule barrier in Gram-
negative bacteria, its structure is crucial for the sensibility of the pathogen to a variety of host 
proteins or metabolites, and to drugs (Whitfield and Trent 2014). Indeed, the LPS net electric 
charge  is negative owing to different moieties such as acyl chains and phosphoethanolamine, 
that shields the bacteria from most antimicrobial peptides released by the host immune system 
that have a net positive charge and are termed “cationic antimicrobial peptides” (Kanazawa, 
Sato et al. 2009, Anaya-Lopez, Lopez-Meza et al. 2013). It also avoids recognition by TLR4 
receptors (Wang and Quinn 2010) (see below). The excessive host responses to LPS and more 
specifically to Lipid A that is pro-inflammatory can lead to systemic inflammatory conditions 
from sepsis, to severe sepsis, and fatal septic shock. TLR4 pro-inflammatory signaling has 
also been associated with pathological responses to endogenous ligands in autoimmune 
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disorders and chronic inflammatory conditions accompanying development of atherosclerosis, 
neurodegenerative diseases, and others (O'Neill, Bryant et al. 2009, den Dekker, Cheng et al. 
2010, Trotta, Porro et al. 2014). 
 
I-3.3.4 LPS/TLR4 signal pathway 
The Toll proteins were first detected in Drosophila, as necessary for the modeling of 
dorsal-central development of territories during embryogenesis (Anderson, Jurgens et al. 
1985, Morisato and Anderson 1995). It was further recognized as pivotal in the initial stages 
of the innate immune response (Lemaitre, Nicolas et al. 1996, Cherry and Silverman 2006). 
Toll-like receptors (TLRs) are part of the PRR family and mediate pathogen-associated 
molecular pattern (PAMP)-induced signalling (Romani 2004). LPS can bind to TLR4 and 
activate the transcription factor nuclear factor κB (NF-κB), a key player in the inflammation 
process that up-regulates the expression of many genes (Imler and Hoffmann 2001, Wan and 
Lenardo 2010). The activation of TLR4 starts from an interaction of LPS with LPS-binding 
protein (LBP) circulating in blood. LBP facilitates extraction of LPS monomers from LPS 
aggregates by CD14 (Yu and Wright 1996, Iovine, Eastvold et al. 2002),a GPI-anchored 
glycoprotein at the surface of monocytes, macrophages, dendritic cells, and at a lower level, 
neutrophils (Goyert, Ferrero et al. 1988, Simmons, Tan et al. 1989). Subsequently, CD14 
transfers the LPS to MD-2 (Lymphocyte antigen 96) in the TLR4/MD-2 complex (da Silva 
Correia, Soldau et al. 2001, Gioannini, Teghanemt et al. 2004, Gioannini, Teghanemt et al. 
2005). By simultaneously binding to MD-2 and to the adjacent TLR4 receptor, LPS facilitates 
formation of TLR4/MD-2 complexes (Nagai, Akashi et al. 2002, Ohto, Fukase et al. 2007, 
Park, Song et al. 2009, Resman, Vasl et al. 2009). The TLR4 complex recruits two pairs of 
adaptor cytoplasmic proteins, TIRAP/MyD88 and TRAM/TRIF, to the TIR domain of the 
receptor by homotypic TIR–TIR interactions. MyD88 then recruits the IRAK4 and IRAK2 (or 
IRAK1) kinases so-called myddosome (Motshwene, Moncrieffe et al. 2009, Lin, Lo et al. 
2010). This multimolecular complex triggers a signaling cascade leading to activation of NF-
κB and MAP kinases and the up-regulation of pro-inflammatory cytokines like tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6). On the other hand, TRIF initiates a signaling pathway 
which leads to the expression of interferons (IFN) type I and IFN-inducible chemokines like 
IL-10, late-phase activation of  NF-κB and MAP kinases follows (Kawai and Akira 2011). 
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Figure 4: LPS recognition by the TLR4/MD2/CD14 complex. LPS circulates in blood 
bound to LBP protein. The main LPS binding site is a large N-terminal highly hydrophobic 
pocket of CD14 monomers (Kim, Lee et al. 2005, Kelley, Lukk et al. 2013). The hydrophobic 
pocket of the adaptator protein MD-2 accommodates most of the lipid portion of LPS, 
however, the endotoxin interacts with the ectodomain of TLR4 molecule. Additionally, the 
phosphate groups of lipid A interact with positively charged amino acids of TLR4. Homotypic 
TIR–TIR domain interactions allow the formation of the signaling complex and the 
recruitment of downstream pro-inflammatory effectors leading to the up-regulation of 
cytokines and type 1 interferon. Adapted from (Plociennikowska, Hromada-Judycka et al. 
2015) 
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Chapter Two 
Microparticles and vascular damage  
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II-1.1 Overview and physiopathological significance  
The Microparticles (MPs) also termed microvesicles (MVs) are plasma membrane 
vesicles capable of transmitting a pro-inflammatory message to neighboring or remote target 
cells (Haddad 2002, Delabranche, Berger et al. 2012) (Bonello, Zahringer et al. 2007). Their 
diameter ranges from 50 nm to1µm and they contain cytoplasmic components such as 
proteins, lipids or nucleic acids. They form a storage pool of biologically active messengers 
that are able to diffuse into body fluids.  MVs were first called “ectosomes” and their nature 
and origin are completely different from exosomes that are smaller vesicles released from the 
intracellular late endosomes. MP release occurs after plasma membrane phospholipid 
randomization between the inner and outer leaflets in response to cell activation, (Hugel, 
Martinez et al. 2005). Microparticles (MPs) are shed by cells in response to a variety of 
stimuli such as apoptosis, oxidative stress or inflammation. MPs are released into the 
surrounding extracellular matrix and tissues and into biological fluids. They exhibit the 
distinctive features of the plasma membrane of the cells they were stemmed from, essentially 
membrane proteins (CDs) that allow for the characterization of the MPs cell origin and also 
anionic phospholipids that confers them a procoagulant potential in blood. MPs may convey 
stress-specific activation markers. MP also convey biologically active molecules that were 
present in the plasma membrane or in the cytoplasm at the emission site (lipids, peptides, 
proteins, mRNA), and behave as cellular effectors (Morel, Jesel et al. 2011). Whatever the 
initial stimulation, MPs are reliable hallmarks of cell damage while cells they originate from 
remain sequestered in tissues or are already submitted to phagocytosis.  
MPs also act as cellular effectors. They contribute to inflammatory and homeostatic 
responses, vascular remodeling and angiogenesis, cell survival, and apoptosis, and are known 
actors in atherothrombosis owing to their procoagulant properties (Haddad 2002). Indeed, 
hardly detectable in the peripheral blood of healthy individuals, procoagulant MP circulating 
at elevated levels are often associated with thrombotic propensity (Chironi, Simon et al. 2006, 
Morel, Toti et al. 2006), see below and figure 5.  
 
II-1.2 Membrane remodeling and vesiculation 
 It is generally assumed that MPs form when the plasma membrane loses the 
asymmetrical distribution of lipids between the inner and outer leaflets. Under resting 
conditions, phosphatidylserine (PS) is located exclusively in the inner monolayer (Morel, 
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Jesel et al. 2011). After stimulation, there is a rapid egress of aminophospholipid to the outer 
leaflet, with decreased activity of flippase while floppase activity is induced.  
Owing to a slower compensating phosphaticylcholine transport from the outer to the inner 
leaflet a transient mass imbalance of the exoplasmic leaflet occurs at the expense of the 
cytoplasmic one (Morel, Toti et al. 2006). Ultimately, membrane budding is resolved by the 
release of MPs that expose PS and hijack membrane antigens and cytoplasm components. The 
dynamic balance of cell stimulation, cell proliferation, and death within the vessels is 
reflected by the variation in MP populations that constitute a vascular storage pool. 
Furthermore, MPs modulate a variety of cell responses such as cell death, vasomotricity, 
redox signaling, inflammation, thrombosis, angiogenesis and tissue remodelling. 
 
 
Figure 5: The plasma membrane remodeling and MPs shedding Phospholipids in the 
plasma membrane of resting cells present an asymmetric distribution between the two leaflets 
(left panel). Randomization of phospholipids between the two leaflets of the membrane 
requires cytoskeleton reorganization involving calcium-activated proteases such as caspases 
and calpains. A sustained increase in intracellular calcium ions is mandatory for PS exposure 
during apoptosis, ultimately associated with changes in mitochondrial permeability. The 
exact interplay between ion transport across the membrane, transient transmembrane pores, 
and Stored Operated Channels calcium Entry (SOCE) deserves further investigations to gain 
insight into a potential pharmacological approach to limit anionic phospholipid exposure in 
thrombotic disorders. (Morel, Jesel et al. 2011) 
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II-1.2.1 Phospholipid asymmetry of the plasma membrane in resting cells 
Plasma membrane fluidity is an important factor in maintaining cell function and 
responses to its environment. It is dependent on both temperature and lipid composition. 
Phospholipids, glycolipids and cholesterol ensure the selectivity of the membrane barrier. The 
main phospholipids of the plasma membrane are: phosphatidylcholine (PhChol), 
phosphatidylethanolamine (PhEth), the phosphatidylserine (PS) and sphingomyelin and their 
proportions vary with the cell lineage. The chain length and number of unsaturated links of 
fatty acids determines the flexibility and thickness of the membrane. PS and PhEth are mainly 
located in the inner leaflet Sphingomyelin and PhChol are found on the outer leaflet (Agger, 
Christensen et al. 2008). The distribution of the membrane lipids is the result of an active 
process under the dependence of complementary phospholipids transporters governing either 
the inward (flip) or the outward (flop) translocation. Any appearance of PS or 
phosphatidylethanolamine on the outer leaflets is counteracted by a reverse transport to the 
inner leaflet by an aminophospholipid translocase with flippase activity that maintains the 
normal resting phospholipid distribution (Morel, Jesel et al. 2011). The lateral movements of 
proteins and phospholipids in the same monolayer are part of the membrane's fluidity. This 
transverse diffusion allows the formation of functional platforms known as "lipid rafts" that 
enhance the concentration of specific receptors and phospholipids, PS, being recruited at their 
vicinity (Kunzelmann-Marche, Freyssinet et al. 2002). Of note, PS exposure at cell surface is 
a signal for phagocytosis and a common feature of stimulated, apoptotic and senescent cells. 
In addition, differentiated cells and cancer cells expose higher proportion of PS than their 
counterparts.  
II-1.2.2 The phospholipid transporters 
Basically, the transverse movements between the two layers phospholipids of the 
plasma membrane are rare and slow. However, the transmembrane transport of phospholipids 
play an important role in diverse cellular processes such as the maintenance of the plasma 
membrane, and  asymmetry, vesicular trafficking, the regulation of the functions of 
membrane proteins, phagocytosis, coagulation, and apoptosis (Coleman, Quazi et al. 2013). 
Lipid asymmetry is generated primarily by selective synthesis of lipid on one side of the 
membrane. Because passive lipid trans bilayer diffusion is slow, a number of proteins have 
evolved to either dissipate or maintain this lipid gradient. These proteins fall into three 
classes: 1) ATP-dependent transporter called "flippases", which is highly selective for PS and 
functions to keep this lipid sequestered from the cell surface, 2) ATP-dependent transporter 
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called "floppases, their activity has been associated with ABC class of transmembrane 
transporters, and finally the third ATP-independent transporter called "scramblases", 
nonspecific carrier which ensures homogeneous distribution of lipids reformed in the 
endoplasmic reticulum or in the plasma membrane of a selected cell (Daleke 2003).  
   Under conditions of stress and calcium influx, flippase inactivation; scramblase and 
floppase activation causes membrane phospholipid randomization and the exposure of PS by 
the outer leaflets (Segawa, Kurata et al. 2014). This outsourcing of PS is the expression of 
early apoptosis or cell activation and a signed for phagocytosis (Fadok, Warner et al. 1998).    
Figure 6 : Phospholipid transporters (Clark 2011) 
Transport by flippases is ATP-dependent it leads to the translocation of the 
phosphatidylserine (PS) and, less significantly, phosphatidylethanolamine (PE), from the 
outer leaflet to the inner leaflet of the Plasma Membrane. Symmetrically, floppases use ATP 
to transport phosphatidylcholine (PC), sphingolipid (SL) and cholesterol from cytoplasmic to 
the extracellular leaflet, against the concentration gradient. The activity of the calcium-
dependent scramblases ensures a non-specific movement of the phospholipids according to 
their concentration gradient.  
 
 Interestingly, in Scott syndrome, a rare bleeding disorder characterized by altered flip-
flop and PS translocation at the outer leaflet of the plasma membrane of red blood cells, 
lymphocytes and platelets, MP shedding is also impaired testifying to the hemostatic function 
of MPs. (Toti, Satta et al. 1996). However, no deficiency in activity or mutation of the 
identified scamblases or in flippases could be evidenced. Instead, altered ABC-A1 
transporters that are occasional floppases led to impaired so-called scramblase activity. 
Recently, mutation of the gene of the anoctamine 6, a calcium-dependent chloride channel, 
was identified in homozygous and heterozygous-type Scott patients, indicating that other lipid 
transporters are involved in fli-flop and MP shedding. (Sohal, Mockett et al. 2002, De Luca 
d'Alessandro, Bonacci et al. 2011, Lopez-Otin, Blasco et al. 2013)   
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II-1.2.3 Cell Activation causing MP shedding  
II-1.2.3(1) Calcium influx and disruption of membrane asymmetry 
Many stimuli can lead to cell activation and an immediate or rapid MP release in 
response to acute stress, or to a slower but sustained MP shedding as the result of cell death or 
differentiation. Stimuli include endotoxin, non-esterified cholesterol, thrombin, hypoxia, 
growth factors and inflammatory molecules (IL-1β, TNF-α, Fas, etc.). Cell activation is 
accompanied by a large and sustained increase of intracellular calcium (30-350 µM against 1 
µM at baseline). The intracellular calcium concentration increase is consecutive to the release 
of intracellular stores and to calcium influx (Martinez and Freyssinet 2001). TRPC6 (transient 
receptor potential channel), the SOCE (store-operated channel entry) channels that are 
activated by the emptying of the intracellular stores, but also other calcium channels, promote 
the secondary calcium influx into the cell (Munnix, Harmsma et al. 2003). In addition, 
depolarization of the outer membrane of the mitochondria causes the opening of the 
mitochondrial pores and the release of calcium into the cytosol. Increased calcium 
concentrations inhibit flippase activity and stimulate floppase and scramblase activities 
(Wolfs, Comfurius et al. 2005). Activation of the cells simultaneously leads to a faster 
transfer of PS to the outer leaflet. As a result, the breakdown of membrane asymmetry is the 
main mechanism involved in the emission of MPs. Most likely mechanisms involved in flip-
flop depend on the type of stress and duration, on the physical characteristics of the plasma 
membrane of the cell lineage, on the membrane proteins that may also act on its curvature and 
on cytoskeleton proteins that interact with the inner leaflet anionic phospholipids 
(Lhermusier, Chap et al. 2011), see below. 
 
II-1.2.3 (2) Calcium influx and degradation of the cytoskeleton 
 The excess of the intracellular calcium promotes a calcium-dependent proteolytic 
activity of calpain and other cysteine proteases like caspases. Local protein degradation of the 
cytoskeleton like filamin-1, gelosine, talin and myosin facilitates microparticle budding 
(Morel, Jesel et al. 2011). It is enhanced by caspase activation in the case of apoptotic stress. 
At the initial steps of apoptosis, the concentration of MPs is directly related to the activation 
of caspases: caspase-3 cleaves the Rho kinase ROCK-1 that phosphorylates myosin light 
chain (MLC), inducing the cytoskeleton remodelling and prompting the release of MPs. 
ROCK-2 is similarly activated in thrombin-activated Endothelial cells(Coleman, Sahai et al. 
2001) (Cabelof, Raffoul et al. 2002),Figure 7 
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Figure 7 : Models of phospholipid movements across the plasma membrane bilayer and 
MP release  (Hugel, Martinez et al. 2005).Following stimulation and enhance in 
intracellular calcium concentration, the activity of phospholipid transporters is altered. The 
activation of floppase and inhibition of flippase activities results in an accumulation of PS at 
the outer leaflet of the plasma membrane. 
 
II-2 Pathogenic effects of microparticles in vascular diseases 
Recent data have confirmed that MPs released from senescent endothelial cells play a 
key role in vascular health and disease and that they may orientate the ability of the vessel to 
maintain vascular homeostasis (Sabatier, Camoin-Jau et al. 2009). Ins pathological vessel, 
two distinct groups of MP can be distinguished: (i) circulating MPs released from endothelial 
and circulating blood cells and (ii) MPs sequestered within the atherosclerotic plaque or in the 
vessel wall. MP from the plaque are eventually shed by senescent or apoptotic cells recruited 
into the lipid core and may eventually be released in blood flow after plaque rupture 
(Beckman and Ames 1998, Morel, Morel et al. 2008). 
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II-2.1 Microparticles, coagulation and thrombosis 
The most established property of MPs is their ability to promote coagulation. 
Circulating MP levels are elevated in hypercoagulability disorders. Several studies have 
shown that the amount of circulating MPs, in particular of platelet, endothelial and leukocyte 
origin, is related to the severity of the cardiovascular disease or disorder like pulmonary 
hypertension (Wallace 1994, Ward 1994, Breen and Murphy 1995). The procoagulant 
properties of MPs, mainly due to the exposure of PhSer or TF expression in inducible cells 
(monocytes and endothelial cells mainly), play a central role in the prothrombotic effect of 
MPs. Conversely, in the rare bleeding disorder called Scott syndrome, flip-flop and MP 
shedding are defective, thereby confirming the hemostatic role of MPs in healthy individuals. 
(Hagen 2003) 
In a mice model of endothelial-injury mediated thrombosis, Owens et al. have shown in vivo 
that TF-bearing MPs are incorporated into the growing thrombus (Owens, Passam et al. 
2012). In addition, TF+-MPs are elevated in various thrombotic disorders, which affect the 
arterial or venous beds, or microcirculation. In the arterial compartment, within the 
atherosclerotic plaque, MPs from macrophages or smooth muscle cells harbor at least 90% of 
tissue factor activity (Mallat, Benamer et al. 2000) while they were almost undetectable in 
adjacent healthy tissue or in the mammary artery (Canault, Leroyer et al. 2007). A recent 
study has suggested that circulating endothelial MPs are predictive of plaque instability in 
carotid patients (Wekesa, Cross et al. 2014). 
 
II-2.2 Microparticles and Diabetes 
Plasma pro-coagulant MPs are elevated in diabetes type 2 (T2DM). Cimmino and coll. 
have observed a higher rate of TF-related MPs correlated with increased markers of activation 
of coagulation (Santilli, Marchisio et al. 2016). In addition, the increase in pro-coagulant MP 
in DT1 patients is correlated with HbA1c, suggesting that the pro-coagulant potential of MPs 
is associated with the loss of glycemic control, an eventual cause of cellular damage or 
senescence (Sabatier, Darmon et al. 2002). Endothelial dysfunction is a central pathogenic 
mechanism in the development of vascular complications related to diabetes. The endothelial- 
derived MP concentrations increase during thrombotic complications in DT2 patients and 
EMP convey TF (Tsimerman, Roguin et al. 2011). Ettelaie et al. have shown that TF-bearing 
MPs, released by renal mesangial cells in response to glucose, induce capillary formation in 
human dermal endothelial cells (Ettelaie, Su et al. 2008).  
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Taken together, these data suggest that circulating MPs of endothelial origin and/or bearing 
TF promote a cardiovascular risk profile in diabetes (Sinning, Losch et al. 2011). However, 
the potential mechanisms involved in the increased release of MPs in diabetes remain to be 
characterized. In leptin receptor-deficient diabetic mice the high endothelial MP level was 
positively correlated with blood glucose concentration and infarct volume after ischemic brain 
injury (Chen, Chen et al. 2011). Thus, elevated levels of endothelial MPs have been 
associated with increased levels of plasma-oxidized LDL in T2 DM patients, suggesting that 
oxidized LDLs contribute to vesiculation of the endothelial membrane (Nomura, Shouzu et al. 
2004). 
II-2.3 Microparticles, endothelial dysfunction and inflammation  
Various proinflammatory stimuli cause the release of proinflammatory MPs. This 
process may be considered a form of sterile inflammation, which involves the production of 
pro-inflammatory mediators such as cytokines and chemokines and promotes the secondary 
recruitment of inflammatory cells (Chen and Nunez 2010). Mesri et al. have shown that 
leukocyte MPs promote the release of inflammatory cytokines, IL-6 and MCP-1 and the 
induction of TF via the JNK1 pathway (Mesri and Altieri 1999). In addition, T lymphocyte 
MPs have been reported to induce the production of TNF-a and IL-1β by monocytes (Scanu, 
Molnarfi et al. 2008). Monocyte-derived MPs stimulate IL-8 and MCP-1 production in human 
bronchial epithelial cells (Neri, Armani et al. 2011), and both  monocyte and endothelial MPs 
promote the production of IL-6 and MCP-1 in human podocytes (Eyre, Burton et al. 2011). In 
this respect, treatment with platelet MPs is associated with increased expression of ICAM-1 in 
cultured endothelial cells promoting leukocyte recruitment (Barry, Pratico et al. 1998). In 
addition, monocyte MPs activate the NF-kB pathway and increase the expression of adhesion 
molecules (Wang, Williams et al. 2011). Endothelial MPs have been shown to bind to 
monocytes and promote their transendothelial migration (Jy, Minagar et al. 2004). In a model 
of acute pulmonary injury involvement in rats, the inherent pro-inflammatory effect of 
endothelial MPs was associated with endothelial dysfunction, acute lung injury, increased 
levels of systemic and alveolar pro-inflammatory cytokines (IL-1β and TNF-α), neutrophile 
infiltration into the perivascular space and histological lesions (Densmore, Signorino et al. 
2006, Buesing, Densmore et al. 2011). Similarly, injection of circulating MPs from septic 
patients in mice results in increased expression of iNOS, COX-2, and NF-kB in the heart and 
lungs, leading to vascular dysfunction (Mastronardi, Mostefai et al. 2011). Similar pro-
inflammatory properties of MPs from septic rats  were identified and were found sensitive to 
 33 
pharmacological modulation (Boisrame-Helms, Delabranche et al. 2014) indicating that they 
may constitute a therapeutic target or tool depending on the signal they convey. In humans, 
the relationship between the inflammatory state, the release of MPs and the extent of 
atherosclerosis has been demonstrated in asymptomatic patients with metabolic syndrome 
(Chironi, Simon et al. 2006), see figure 8. 
 
 
Figure 8 : Impact of circulating MPs with procoagulant and pro-inflammatory 
properties on the endothelium and vessel wall (Amabile, Guignabert et al. 2013) 
 
II-2.4 MPs and oxidative stress in the endothelium 
Several studies have highlighted the properties of MPs as cellular effectors of 
oxidative stress in blood vessels. Tual et al. have shown that hypoxic circulating MPs 
promote endothelial dysfunction in rat aorta and pulmonary arteries by reducing NO 
production, a key regulator of endothelial survival. In addition, these MPs exhibited tissue 
specificity with oxidative stress preferentially induced in pulmonary endothelial cells (Tual-
Chalot, Guibert et al. 2010). The deleterious action of the MPs is confirmed in vivo by the 
injection into mice of circulating MPs isolated from patients with the metabolic syndrome 
which reduces the endothelium-dependent relaxation and the expression of eNOS and hence 
also the production of NO confirmed in endothelial cell cultures (Agouni, Lagrue-Lak-Hal et 
al. 2008). Cheng et al., have shown in vitro that circulating endothelial MPs cause endothelial 
dysfunction via Nox4 expression and ROS production in human umbilical vein endothelial 
cells (HUVECs) (Cheng, Wang et al. 2013). Other studies specified a role for T lymphocyte 
MPs that decrease NO production and increase oxidative stress in endothelial cells via 
 34 
xanthine oxidase (Mostefai, Agouni et al. 2008). Monocyte MPs induce endothelial 
production of ROS, mainly superoxide anion, parallel to rapid expression of von Willebrand 
factor at the endothelial surface, and induction of functional TF, via NADPH oxidase, 
mitochondria, xanthine oxidase and cyclooxygenase (Essayagh, Xuereb et al. 2007, Terrisse, 
Puech et al. 2010). Brodsky et al. initially showed that endothelial MPs decrease NO 
production in rat aortic rings and was associated with the impaired endothelial function 
(Brodsky, Zhang et al. 2004). All of these findings identify endothelial dysfunction mediated 
different sources of MP. Abbas et al. have identified the role of oxidative stress in autocrine 
endothelial dysfunction induced by senescent MPs and likely to circulate in the plasma of 
patients with the acute coronary syndrome. These MPs induce ROS accumulation and 
increased expression of NADPH oxidase subunits in young endothelial cells (Abbas, Jesel et 
al. 2017). 
 
II-2.5 Microparticles and senescence 
Several studies have suggested a relationship between endothelial senescence and 
MPs. Burger's team showed in a mouse model that treatment of primary aortic endothelial 
cells by MPs or H2O2 was associated with a nonproliferative phenotype, meaning that MPs 
induce premature senescence, which was established via the NADPH oxidase and 
mitochondrial ROS measurement expression (Burger, Kwart et al. 2012). Brodsky et al. 
showed that the development of accelerated vasculopathy in Zucker diabetic rats was 
characterized by a 6-fold increase in the number of senescent endothelial cells, an increase in 
MP levels, a decrease in NO production and vasorelaxation (Brodsky, Gealekman et al. 
2004).  
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Chapter Three 
Structure and Physiology of Endothelium 
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III-1 Blood vessels 
 Blood vessels play an essential role in the vascular homeostasis through a complex 
network comprised of arteries, capillaries, and veins (Chiu and Chien 2011). Blood vessels 
constituted of distinct histological regions containing smooth muscle cells and elastin. The 
tunica intima includes a simple layer of lining the vessel cavity and the internal elastic lamina 
membrane which is highly elastic, enriched in collagen fibers and supported by a basement 
membrane (or basal lamina). In close juxtaposition to the endothelial cells, perivascular cells 
or pericytes can differentiate into a wide variety of cells (fibroblast, adipocytes and smooth 
muscle cells). They act as scaffold system providing balanced microenvironment for the 
endothelial cells lacking blood supply (Chakravarthy and Archer 1992).  
The tunica media consists of smooth muscle cells and elastic connective tissue. It is 
separated from adventitia by external elastic lamina. The media is responsible for 
vasoconstriction and vasodilation, the two physiological phenomena responsible for the 
regulation of vascular tone. 
The last and outermost layer of the blood vessel is the tunica adventitia, composed of 
collagen and elastic fibers (Gutterman 1999).  Its inner side is surrounded by elastic lamina. It 
consists of nerves and lymphatic vessels, and contains small blood vessels known as vaso 
vasorum. The vasa vasorum consist of arterioles and provides the adequate blood supply for 
areas far from the lumen (Pugsley and Tabrizchi 2000), see figure 9. 
 
III-2 Endothelium: overview of its function  
The term endothelium was coined in 1865 by the anatomist Wilhelm His, who 
differentiated the inner lining of body cavities from the epithelium. The endothelial 
monocellular layer separates all tissues from the circulating blood (Minami and Aird 2005, 
Gori, Dragoni et al. 2007). In the shape, endothelial cells (ECs) are generally flat (Gori, 
Dragoni et al. 2007). The endothelium is characterized by structural and functional 
heterogeneity as the shape and organization of cells vary across the blood vessels tree. Blood 
vessel endothelium traverses each and every tissue, but each vascular bed has unique 
structural and functional properties (Aird 2007). It is heterogeneous, and are classified into 
three types: 1) the continuous endothelium found in most arteries, veins, and capillaries of the 
brain, skin, lungs, heart, and muscles. ECs are contiguous and maintained by narrow junctions 
at the continuous basement membrane. 2) The fenestrated endothelium is also connected to a 
continuous basement membrane but is characterized by the existence of trans-cellular pores 
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50 to 60 nm wide. 3) The discontinuous endothelium, which is associated with a poorly 
structured basement membrane, is characterized by large fenestrations of 100 to 200 nm in 
width. This type of endothelium is found largely in the liver, spleen and bone marrow (Aird 
2007). 
 
 
Figure 9: A schematic representation of blood vessels and their components. Adapted 
from Wayne W. La Morte, MD, PhD, MPH, Boston University School of Public Health. 
 
 EC thickness varies from less than 0.1 µm in capillaries and veins to 1 µm in the aorta 
(Florey 1966, Aird 2007). ECs are key player in maintaining vascular homeostasis. The 
healthy endothelium is characterised by a hemocompatible phenotype and  anti-inflammatory 
and vasodilatory properties whereas endothelial dysfunction is characterised by reduced 
vasodilatory responses to flow or agonists, is inflamed and procoagulant (Celermajer, 
Sorensen et al. 1994, Dohi, Kojima et al. 1995, Deanfield, Halcox et al. 2007). ECs are in 
direct contact with the blood and form a selective barrier between the vessel lumen and the 
surrounding tissues. ECs contain multiple transport systems for amino acids and glucose 
(Galley and Webster 2004). They express or secrete matrix products, anticoagulant or anti-
thrombotic factors, fibrinolysis activators, growth factors such as insulin growth factor, 
inflammatory mediators and are involved in the control of vascular tone by soluble mediators 
or the expression of different receptors for vasoconstrictors or dilators (van Hinsbergh 2012). 
The endothelial function is gradually penetrated with ageing (Taddei, Virdis et al. 1995, 
Favero, Paganelli et al. 2014). A key mechanism responsible for the impairment of 
endothelial function with ageing is thought to be the loss of the endothelium derived nitric 
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oxide (NO), a vaso-relaxing factor, via its interaction with accumulated ROS to form 
peroxynitrite. Peroxynitrite oxidises BH4, an primary cofactor for NO synthesis by 
endothelial nitric oxide synthase (eNOS), to its inactive form resulting in reduced NO 
production (Sindler, Delp et al. 2009), see below. The endothelial dysfunction means damage 
to vascular endothelial, its an initial step in the development and progression of 
atherosclerosis, and the pivotal underlying pathology in the arterial wall (Vanhoutte 2009, 
Gutierrez, Flammer et al. 2013). 
 
Figure 10: Structure of the arterial wall. The arterial wall is composed of three layers: 
tunica intima, tunica media, and tunica external. (Gutterman 1999) 
 
 
 
 
 
 
 
 
 
 
Figure 11 : The different metabolic functions of endothelial cells and endothelial 
mediators (Galley and Webster 2004) 
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III-3 Endothelium and vascular tone  
 The multiple functions of vascular endothelium include regulation of vessel integrity, 
tissue growth and metabolism, vascular growth and remodeling, cell adhesion, immune 
responses, angiogenesis, hemostasis and vascular permeability. The endothelium is the main 
player in the regulation of vascular tone, controlling tissue blood flow and maintaining blood 
fluidity and inflammatory responses (Feletou and Vanhoutte 2006, Moncada and Higgs 
2006). Endothelial cells control vascular tone by releasing several relaxing factors, including 
nitric oxide (NO), endothelium-derived hyperpolarizing factors (EDHF), and prostacyclin. 
NO, produced by endothelial NO synthase (eNOS), is the principal mediator of acetylcholine 
(ACh)-induced, endothelium-dependent, vasodilatation in large conduit arteries. However, in 
small resistance arteries, including those of mesenteric, renal, and coronary circulation, EDHF 
is of increasingly greater significance with decreasing vessel diameter in agonist-elicited 
vasodilatation (Wang, Borrego-Conde et al. 2003, Park, Capobianco et al. 2008, Zhou, Qing 
et al. 2010, Kang 2014). 
III -3.1 Endothelium-derived vasorelaxing factors 
III -3.1.1 Nitric Oxide 
   Nitric oxide (NO) is a soluble and diffusible gas, a highly reactive free radical that acts as a 
messenger molecule in various physiological and pathological processes (Palmer, Ferrige et 
al. 1987, Moncada, Palmer et al. 1991). NO is formed by the oxidation of L-arginine through 
the activation of three different NO synthase (NOS) isoforms, including neuronal NOS 
(nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS) (Sessa, Harrison et al. 1992, 
Xie, Cho et al. 1992). In addition, a fourth type of the mitochondrial NOS (mtNOS). Its 
occurrence and function has been confirmed in many tissues and it seems to be a crucial 
regulator of mitochondrial function (Ghafourifar and Cadenas 2005). The expression of eNOS 
is preferential in ECs but eNOS is also described in smooth muscle cells, cardiomyocytes, 
neurons, and bone cells (Lei, Vodovotz et al. 2013). The loss of endothelial NO function is 
associated with several cardiovascular disorders which is due either to decreased production 
or to increased degradation of NO (Davignon and Ganz 2004). eNOS plays a key role in the 
physiological regulation of the cardiovascular system since abnormalities in its productions 
and/or bioavailability accompany or even precede diseases such as hypertension, 
atherosclerosis, and angiogenesis associated disorders (Moncada and Higgs 2006, Pacher, 
Beckman et al. 2007, Vanhoutte 2009, Vanhoutte, Shimokawa et al. 2009). 
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The eNOS/NO functioned as powerful angiogenic mediators and can induce endothelial cell 
proliferation, migration, and tube formation (Kimura and Esumi 2003, Zhao, Vanhoutte et al. 
2015). eNO synthase is activated by intracellular calcium in response to changes in 
mechanical distension (shear stress) caused by blood flow to the vascular wall or via receptor-
mediated processes. Released NO activates soluble guanylate cyclase (GC) in smooth muscle 
cells, converting GTP to cGMP. This activates protein kinases that lead to inhibition of 
calcium flux in smooth muscle cells, and decreased calcium-calmodulin stimulation of the 
myosin light chain kinase thereby reducing smooth muscle tension and causing vasodilation 
(Harrison 1997), see figure 12.  
Agonists, such as acetylcholine, bradykinin and histamine, bind specific endothelial receptors 
that mediate the elevation of intracellular calcium concentrations which activates eNOS to 
produce nitric oxide (NO). Activation of eNOS also occurs independently of the calcium 
concentration via eNOS phosphorylation. The responses to hemodynamic shear stress and 
hormones are mediated mainly through this calcium-independent pathway (see figure 12).  
ECs from old donors are more sensitive to apoptotic stimuli and produce less NO in response 
to physiological stimuli. In aging aorta, the reduced NO production seems associated with 
calcium-independent e-NOS activation 
 
Figure 12 a: Endothelial nitric oxide synthase (eNOS) can be activated in calcium-
dependent or- independent ways and favors vasodilatation through NO production 
(Zhao, Vanhoutte et al. 2015).  
 
III-3.1.1(1) The kinin system 
Biologically active kinins, including bradykinin (BK) and Lys(0)- BK, are short-lived peptide 
circulating mediators predominantly generated by the enzymatic action of kallikreins on 
kininogen precursors (Howl and Payne 2003)  and they potent endothelium-dependent 
vasodilators that contribute to vasodilation and hypotension. The kinin system consists of 
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substrates (kininogens) and plasma and tissue kallikreins their specific activators producing 
the two vasoactive peptides bradykinin and kallidin. The effects of kinins are mediated via B1 
and B2 specific receptors. BK is key for blood pressure regulation and in inflammatory 
reactions. It acts through its ability to elevate vascular permeability and to cause 
vasodilatation of arteries and veins of the gut, aorta, uterus, and urethra. BK also triggers the 
release of other mediators such as nitric oxide in inflammatory (Wu, Akaike et al. 2002). The 
kinin system is involved in many clinical situations including septic shock, heart diseases, 
respiratory allergic reactions, hypertension and its treatment, hypotensive transfusion 
reactions, pancreatitis, hereditary and acquired angioedema, Alzheimer disease and liver 
cirrhosis with ascites (Agostoni and Cugno 2001). Kinins act via their G protein-coupled 
receptors.  
 
III-3.1.1(2) Bradykinin formation and physiological significance 
The levels of kinin peptides in tissues are higher than in blood, confirming the primary 
tissue localization of the kallikrein-kinin system. Kallikreins are produced by the inactive 
precursors prekallikreins after activation in plasma-mediated by Factor XII (Hageman factor). 
Kallidin is transformed into bradykinin by the enzymatic action of a plasma aminopeptidase. 
Many studies measuring bradykinin and kallidin peptides demonstrated the differential 
regulation of the plasma and tissue kallikrein-kinin systems. In addition, studies have 
demonstrated that kinin peptide levels are enhanced in the heart of rats with myocardial 
infarction, in tissues of diabetic and spontaneously hypertensive rats, and in the urine of 
patients with interstitial cystitis, suggesting a potential role for kinin peptides in the tissue 
response to such pathological conditions (Leeb-Lundberg, Marceau et al. 2005). 
III-3.1.1(3) Transduction of signals from B1 and B2 BK receptors 
BK interacts with its G protein-coupled B1 and B2 receptors  and initiates the 
elevation of intracellular calcium concentration and involves several mediators such as 
phospholipase C, prostagladins, protein kinwase and phospholipase A (Blaukat 2003). The 
hyperpolarizing phase of the cell response to BK may be due to inositol 1,4,5- trisphosphate-
dependent release of stored Ca2+ into the cytoplasm, which activates Ca2+-dependent K+ 
channels. The depolarizing phase of the cell response to bradykinin is due largely to inhibition 
of M channels, thereby decreasing K+ efflux from cells and, to a lesser extent, to activation of 
Ca2+-dependent ion channels and Ca2+ channels (Higashida, Streaty et al. 1986). The 
mitochondrial ATP-sensitive K+ channels act as downstream targets of PKC (Li and Sato 
2001). BK B2 receptors can mediate cardioprotective preconditioning of guinea pig hearts by 
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the dual activation of PKC and PI3-K. In addition, the binding of BK to its B2 receptor 
induces IL-6 expression in airway smooth muscles cells via ERK1/2 and p38 MAP kinase 
signaling pathways. Moreover, the IL-6 secretion by BK proved to be sensitive to 
corticosteroids and was regulated by Thi2-cytokines (Huang, Tliba et al. 2003). 
The bradykinin receptors B1 and B2 are important mediators of cardiovascular homeostasis. 
However, the tissue distribution of BK receptors is wide, and they are detected in tissues such 
as uterus, intestine, kidney, heart, and aorta. The B2 receptor would play a key role in 
cardiovascular pathologies with hypertensive component. The activation of B2 receptors by 
bradykinin promotes the release of prostacyclin and NO production by activating endothelial 
NO synthase (eNOS)(Luckhoff, Busse et al. 1987, Schini, Boulanger et al. 1990, Vanhoutte, 
Zhao et al. 2016). This increase is partially associated with enhanced 
phosphorylation/dephosphorylation of eNOS by many protein kinases and phosphatases (Bae, 
Kim et al. 2003).  The B2 receptor is involved in the acute phase of inflammation and of 
somatic and visceral pain. Conversely, the B1 receptor participates in the chronic phase of 
these responses and is likely to play a strategic role in diseases with a strong immune 
component such as rheumatoid arthritis, multiple sclerosis, septic shock and diabetes (Gabra, 
Couture et al. 2003). 
 
Figure 12 b:  B1 and B2 signalling pathways in ECs and smooth muscle cells 
 (Madeddu, Emanueli et al. 2007) 
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III-3.1.1(4) BK receptors as therapeutical targets 
In many animal and human models, it has been shown that the stimulation of BK B2 
receptors is not only involved in causing inflammation, pain and tissue injury but also brings 
powerful cardioprotective mechanisms. Either exogenous administration of BK or locally 
increased BK concentrations as a consequence of the inhibition of its metabolic breakdown by 
angiotensin converting enzyme inhibitors, reveals the significant contribution of BK in 
powerful cardioprotective mechanisms (Heitsch 2003) mainly caused through vasorelaxant, 
anti-hypertrophic and anti-atherosclerotic endothelial mediators such as NO, prostaglandins 
and tissue-type plasminogen activator. Such mediators are elevated by ischaemic 
preconditioning and in insulin sensitivity. Thus, BK B2 receptor agonists may have value in 
the treatment and prevention of various cardiovascular disorders such as ischaemic heart 
disease, hypertension, left ventricular hypertrophy, ventricular remodeling, and congestive 
heart failure as well as diabetic disorders. However, this potential should be balanced with the 
pro-inflammatory signalling of B1 receptors in chronic diseases. (see above) 
 
III-3.1.2 Endothelium-derived hyperpolarizing factors (EDHF) 
The key effector in control of endothelium-dependent EDHF-evoked vasorelaxation in small 
arteries is hyperpolarization through opening of various types of potassium and calcium-
activated K+ channels (KCa) (Feletou and Vanhoutte 2006) (Zhou, Qing et al. 2010, Mori, 
Suzuki et al. 2011, Kang 2014, Seki, Goto et al. 2017). Although its nature still raises many 
questions, its mechanism of action implies an increase in the intracellular concentration of 
calcium, followed by the opening of calcium-dependent potassium channels of low and 
medium conductance, SKCa and IKCa respectively (Vanhoutte, Zhao et al. 2016).  
 Activation of IKCa and small conductance SKCa favors potassium ions release from ECs, 
leading to their hyperpolarization. Low concentrations of potassium ions in the extracellular 
space can activate inwardly rectifying K+ (KIR) channels and Na+/K+-ATPase to cause 
hyperpolarization of smooth muscle cells through the release of potassium ions by smooth 
muscle cells (Feletou, Verbeuren et al. 2009). EDHF can be induced by various agonists such 
as acetylcholine or bradykinin or calcium ionophore A23187 or thapsigargin, an inhibitor of 
sarco / endoplasmic reticulum Ca2+ ATPase (SERCA) that are responsible of calcium re-
uptake by the endoplasmic reticulum.  
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III-3.1.3 Prostacyclin (PGI2) 
In addition to the release of NO, ECs can also induce, under certain conditions, the 
release of prostacyclin (PGI2), the main metabolite of arachidonic acid (AA). It is produced 
by the sequential actions of phospholipase A2 (PLA2), cyclooxygenase-1 (COX-1) and 
prostacyclin synthase (PGIS). The synthesis of PGI2 can be stimulated by shear forces, 
hypoxia, or following activation of membrane receptors by thrombin, bradykinin, and growth 
factors. This synthesis is calcium-dependent and regulated by different signaling pathways, 
such as phosphorylation modification of certain transcription factors. For example, binding of 
thrombin to its PAR-1 receptor activates MAPKs which causes phosphorylation of serine 505 
and activation of cytosolic PLA2, leading to an increase in the release of AA and the rapid 
synthesis of PGI2 by COX-1. In addition, activation of PAR-1 and PAR-2 increases the 
activity of the NF-κB transcription factor, which promotes inducible COX-2 expression and 
leads to sustained synthesis of PGI2 (Wheeler-Jones 2008). PGI2 acts primarily via the 
prostacyclin (PI) membrane receptor to stimulate soluble adenylyl cyclase to form cyclic 3 ', 
5' adenosine monophosphate (cAMP) which, in turn, activates protein kinase A-dependent 
pathways and may also cause vasodilatation via inhibition of Rho kinase and drop of calcium 
concentration. Under physiological conditions, the vasodilatory properties of PGI2 are often 
masked by those of NO (Vanhoutte, Zhao et al. 2016). However, in pathological conditions 
such as diabetes, the effect of PGI2 seems to be preponderant. Indeed, PGI2 participates 
actively in the acetylcholine-induced relaxations in the diabetic dog coronary artery 
(Gebremedhin, Koltai et al. 1988) and in the diabetic mouse aorta (Shen, Ye et al. 2003). In 
addition, oral administration of prostacyclin analogue normalizes endothelium-dependent 
acetylcholine relaxation in the aorta of diabetic rats (Matsumoto, Morishita et al. 2002).     
 
III-.3.2 Endothelium-derived vasocontracting factors (EDCF) 
III-3.2.1 Reactive oxygen species (ROS) 
Oxidative stress is characterized by the excessive generation of reactive oxygen 
species (ROS), such as superoxide anion, hydrogen peroxide, hydroxyl radical and 
peroxynitrite. ROS are important mediators of inflammation that are the principle for immune 
response and host defenses. ROS are produced and released from ECs under physiological 
conditions and involved in vascular homeostasis. However, excessive ROS production is 
observed in hypertension, diabetes mellitus, acute and chronic inflammatory diseases and 
aging. A variety of enzymes contributes to ROS production including cytochrome P450, 
cyclooxygenases (COXs), lipoxygenases, uncoupled-eNOS, xanthine oxidase, NADPH 
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oxidase (p22phox, p47phox, gp91phox). In addition, the mitochondrial electron transport 
chain is an important source of endothelial ROS under physiological or pathological 
conditions (Griendling and Ushio-Fukai 1997). Mitochondria play a key role in production, 
because the majority of cellular ROS are generated by oxidative phosphorylation, a 
mitochondrial process in which electrons are extracted from NADH and FADH and then 
transferred to molecular oxygen by a chain of 4 complex enzymatic assays for the 
phosphorylation of ADP in ATP and the reduction of molecular oxygen in water. ROS are by-
products of several metabolic and enzymatic pathways and highly reactive due to the presence 
of unpaired electrons in their outer layer. These electrons can react directly with oxygen 
acceptors to generate ROS.  
It has been suggested that less than 2% of total oxygen consumption is diverted for 
ROS generation (Chance, Sies et al. 1979). Low concentrations of ROS are necessary for 
proper cell function (Werner and Werb 2002). Produced in excess, ROS interact with a large 
number of molecules: proteins, lipids, polysaccharides and nucleic acids, which can 
irreversibly alter the function of the target molecule and thus disrupt the cellular response. 
The production of ROS is often self-amplified. For example, ROS released during the 
respiratory process damage mitochondrial DNA, which, unlike nuclear DNA, does not have a 
repair mechanism. The mutations thus induced in the mitochondrial genome cause functional 
abnormalities of the respiratory chain favoring an excessive production of ROS (Miquel 
1998). In addition, the superoxide anion can undergo exaggerated production of hydrogen 
peroxide H2O2 (Bienert, Schjoerring et al. 2006). The latter does not have unpaired electrons 
and is more stable than the superoxide anion. It diffuses everywhere in the cell and gives rise, 
via reactions of the "Fenton" type, to the generation of most deleterious of the ROS, the 
radical hydroxyl (•OH) (Valko, Leibfritz et al. 2007). 
H2O2 + Fe2+               •OH + OH- + Fe3+ 
H2O2 + Cu2+               •OH + OH- + Cu3+ 
The main contribution of oxidative stress to the atherosclerotic burden in human or in animal 
models has been supported by earlier works that have shown an improvement of various 
parameters of the endothelial function under antioxidants therapies (Kanani, Sinkey et al. 
1999, Aubin, Carrier et al. 2006, Holowatz, Thompson-Torgerson et al. 2007, Liu, You et al. 
2007).  
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III -3.2.2 Thromboxane A2 & Prostaglandin H2 (TxA2 & PGH2) 
TXA2 and PGH2 are generated subsequently to the metabolism of arachidonic acid 
(AA) by COX-1 and COX-2 in endothelial cells (Oates, FitzGerald et al. 1988). PGH2 is the 
precursor of the prostaglandins E2 (PGE2α), F2 (PGF2α) and TXA2. By thromboxane synthase 
in platelets, PGH2 synthesizes TXA2, that promotes platelet activation and aggregation, 
vasoconstriction, and smooth muscle proliferation. In smooth muscle cells, it causes an 
increase of intracellular Ca2+ elevation via binding to thromboxane-prostanoid (TP) receptors 
and favors vasoconstriction (Vanhoutte and Tang 2008). In normal vessels, regulation of 
TXA2 and PGI2 is essential since they have opposing functions in maintaining of vascular 
homeostasis. In particular, their ratio seems to be more important than their absolute amounts 
in pulmonary vascular diseases (Caughey, Cleland et al. 2001). 
 
III-3.2.3 Angiotensin  
Angiotensin II (Ang II) is a powerful vasoconstrictive hormone of the renin-
angiotensin system (RAS), which is formed after Ang I is converted to Ang II by the 
Angiotensin I Converting Enzyme (ACE). Ang II is a multifunctional hormone: in addition to 
its ability to cause vasoconstriction, it acts on cell growth, hormone secretion, and neuronal 
activities. In general, RAS is involved participates in various cardiovascular pathologies such 
as left ventricular hypertrophy, post-infarct remodeling, or neointima formation (Zhuo and Li 
2011). Ang II effect is mediated through the G-protein coupled receptors AT1 and AT2 
(Horiuchi, Akishita et al. 1999). AT1 receptor is involved in the regulation of vascular cell 
proliferation or cell death (Csikos, Gallinat et al. 1997). AT2 participates in the transduction 
of various anti-apoptotic or survival pathways. Within the vascular wall, Ang II is also known 
to be a potent stimulant for ROS production through NADPH oxidase activation (Lerman 
2007).    
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Figure 13: Synthesis of endothelium-dependent relaxation and contraction 
pathways. EDRFs: Endothelium Derived Relaxation Factors; EDCFs: Endothelium 
Derived Contraction Factors (from Feletou M. and Vanhoutte P. et al, 2009)(Feletou 
and Vanhoutte 2009) 
III-4 Age-related endothelial dysfunction 
Fluid-induced vasodilation, an indicator of the health status of the endothelium, gradually 
decreases in humans after 50 years (Taddei, Virdis et al. 2001). Epidemiological studies have 
identified age as the leading risk factor for cardiovascular morbidity and mortality (Lakatta 
and Levy 2003).(Shih, Lee et al. 2011). Aging is characterized by a gradual change in the 
structure and function of the vessel leading to a dysfunction of ECs and CML. The thickness 
of the vascular wall increases two to three times between 20 and 90 years and the media 
shows an increase in collagen and elastin content, which increases vascular resistance and the 
risk of atherosclerosis (Lakatta and Levy 2003). A meta-analysis showed that a 0.1 mm 
increase in intima-media thickness (IMT) of the carotid artery (a marker of vascular disease 
used clinically) is associated with an 18% increase in risk stroke and 15% risk of myocardial 
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infarction (Lorenz, Markus et al. 2007). The old CML acquire a proliferative, migratory and 
secretory phenotype. Old ECs show low eNOS expression and decreased NO production, 
accompanied by increased formation of ROS and pro-inflammatory molecules, 
vasoconstrictor prostanoids and endothelin-1 (Sato, Kaji et al. 1993, Minamino, Miyauchi et 
al. 2002).  
ECs isolated from older donors show a decrease in NO synthesis in response to 
mechanical stimuli or agonists, accompanied by increased sensitivity to apoptotic stimuli 
(Matz, Schott et al. 2000, Hoffmann, Haendeler et al. 2001). The loss of PI3K / Akt-
dependent eNOS phosphorylation appears to be the primary mechanism for reducing NO 
production in aged rat aortas (Smith and Hagen 2003).  
The older vessels show impaired endothelial relaxation. This has been observed in 
different vascular beds, such as the rat mesenteric artery and the brachial artery in humans, 
and involves a reduction in both NO and EDH components and is often associated with an 
increase in EDCF responses involving COXs (Vanhoutte and Tang 2008). A decrease in 
calcium-dependent potassium channel expression has also been observed in elderly rat 
coronary arteries (Marijic, Li et al. 2001, Herrera, Mingorance et al. 2010). 
 
III-5 Hyperglycemia and vascular toxicity (glucotoxicity) 
The mechanisms linking hyperglycemia to CV events have not been fully elucidated. 
However, a triad consisting of vascular inflammation, oxidative stress and endothelial 
dysfunction is considered central and creates a vicious circle favorable to the establishment of 
a pro-atherothrombotic endothelium. Substantial clinical and experimental evidence 
demonstrated that impaired endothelium-dependent relaxation existed consistently in both 
conduit and resistance arteries of diabetes mellitus (Leo, Joshi et al. 2012, Freidja, Vessieres 
et al. 2014, Salheen, Panchapakesan et al. 2015). 
 
III-5.1 Hyperglycemia and endothelial and vascular dysfunction 
Chronic hyperglycemia induces endothelial dysfunction characterized by a decrease in 
endothelium-dependent relaxation in different vascular beds (De Vriese, Verbeuren et al. 
2000, Shi and Vanhoutte 2009). Several factors seem to contribute to endothelial dysfunction 
related to diabetes. 
Reduction of NO bioavailability, due to a decrease in the expression and phosphorylation of 
eNOS (Matsumoto, Shimabukuro et al. 2014) and increased production of ROS (Alves-Lopes, 
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Neves et al. 2016) constitute a major cause of dysfunction. In murine diabetic models, a 
decreased expression of eNOS is observed in the heart (Lei, Li et al. 2013, Peng, Chen et al. 
2015), in the ECs of cerebral vessels (Poittevin, Bonnin et al. 2015), glomerular (Hou, Huang 
et al. 2014) and retina (Omae, Nagaoka et al. 2013). Conversely, overexpression of eNOS in 
transgenic diabetic mice improves cerebral vascular reactivity (Chandra, Mohan et al. 2016), 
and administration of substances that can increase endogenous production of NO (L-arginine 
or arginase inhibitors) in diabetic animals, improve cardiomyopathy, preserve renal function 
(Claybaugh and Decker 2014, Hsu, Lee et al. 2015) and restores the blood flow of the 
posterior ischemic limbs (Bir, Pattillo et al. 2014, Kant, Kumar et al. 2015).  
An increase in EDCF production has also been observed in diabetic animals. Contractions 
mediated by EDCF are increased in the conductance arteries, such as the aorta and renal 
artery (Kagota, Yamaguchi et al. 2000) and in the arteries of resistance such as the mesenteric 
artery diabetic rats (Vessieres, Guihot et al. 2013). 
Another contributor to diabetes-related endothelial dysfunction is ET-1b that promotes 
vasoconstriction and inflammation. Glycemic control by administration of Metformin to 
diabetic rats has been shown to prevent activation of the endothelin system with 
normalization of ET1 plasma levels and decreased expression of the ET A receptor in the 
mesenteric artery (Sachidanandam, Hutchinson et al. 2009). In addition, ET receptor 
antagonists prevent vascular remodeling and cerebrovascular dysfunction in the middle 
cerebral arteries of Goto-Kakizaki diabetic rats (Harris, Hutchinson et al. 2005, Kelly-Cobbs, 
Elgebaly et al. 2011). Administration of ACE inhibitors improves endothelial function 
measured by FMD in type 1 diabetic patients with normal blood pressure (Arcaro, Zenere et 
al. 1999), indicating a key role of the RAS.  
 
III-5.1.1 Role of the angiotensin system in senescence induced by hyperglycemia 
Meta-analysis of several clinical trials showed that inhibition of RAS decreased the 
number of new diabetic patients (Abuissa, Jones et al. 2005, Yusuf, Ostergren et al. 2005). In 
addition, clinical trials have shown a beneficial CV effect of ACE inhibitors and Sartans in 
diabetics.  
Chen et al., showed that EC exposure to high glucose (HG) increases SA-β-gal activity and 
mitochondrial oxidative stress, accompanied by overexpression of the conversion enzyme, 
and AT-receptor 1 of Ang II. The treatment of ECs with ACE inhibitors (benazepril) or 
Sartans (Losartan) inhibits HG-induced senescence and mitochondrial oxidative stress, 
suggesting a key role of the RAS system in glucose-induced endothelial senescence. Thus, the 
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deleterious effects of chronic hyperglycemia on vascular function could contribute to the 
development of cardiovascular disease (CVD) in diabetics. (see also endothelial senescence, 
chapter IV) 
 
III-5.2 Hyperglycemia and inflammation 
High levels of cytokines and inflammatory factors such as TNFα, interleukin-6, 
soluble ICAM, MCP-1 protein and soluble E-selectin have been found in the serum of 
diabetic patients and animals (Fukui, Tanaka et al. 2013, Leguina-Ruzzi, Pereira et al. 2015, 
Wu, Liang et al. 2016). Indeed, hyperglycemia via ROS generation induces the expression of 
redox-sensitive genes (the major redox-sensitive transcription factor is NF-kB) leading to a 
pro-inflammatory phenotype by overexpression of adhesion molecules (VCAM-1) and pro-
inflammatory cytokines (IFNγ), and pro-coagulant by overexpression of tissue factor (FT), 
leading to recruitment and infiltration of monocytes, and activation of the coagulation 
cascade. All of these events create an endothelial and vascular environment that is conducive 
to atherothrombosis, and in a higher proportion in patients with T2D than in patients with 
degree of CV risk similar but free from diabetes. 
 
III-5.3 Hyperglycemia and oxidative stress 
In diabetes, the increase in oxidative stress is attributed to the increased production of 
ROS and the alteration of antioxidant defenses. Indeed, an increase in the expression of 
NADPH oxidase (Kowluru, Kowluru et al. 2014, Shida, Nozawa et al. 2014, Li, Wang et al. 
2015) and COX-2 (Roy, Kim et al. 2015), as well as a decrease in the expression of 
manganese superoxide dismutase (SOD) (Wang, Li et al. 2015) have been observed in the 
vessels of T2D patients and of diabetic animals. For instance, vitamin C significantly 
improved endothelium-dependent vasodilation in these patients (Ting, Timimi et al. 1996). 
The oxidative stress linked to hyperglycemia is of multiple origine. 
 
 
 
III-5.3.1 Auto-oxidation of glucose 
Glucose, in its ene-diol form, in the presence of transition metals, gives rise to an 
anionic radical ene-diol; this, by reducing the molecular oxygen, releases superoxide anions 
with the concomitant formation of a carbonyl compound. The superoxide anion can be 
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disproportionated to hydrogen peroxide which in turn produces hydroxyl radicals in the 
presence of transition metals (Delattre, Bonnefont-Rousselot et al. 1999). 
 
III-5.3.2 Advanced glycation end-products (AGEs) 
AGEs are formed in hyperglycemic conditions and during aging and contribute to the 
pathophysiology of vascular diseases of diabetes (Schmidt, Yan et al. 1995, Rojas and 
Morales 2004). The most common AGEs in diabetic vessels are relatively inert Nε-
carboxymethyl-lysine and hydroimidazolones, and highly reactive derivatives of methyl-
glyoxal and 3-deoxyglucosone. Indeed, by binding to their membrane receptors (RAGEs), 
members of the family of immunoglobulin-like proteins, AGEs cause the activation of 
multiple signaling pathways targeting NADPH oxidase, p21, MAPK and the NF-kB 
transcription and target genes, thus promoting oxidative stress and an inflammatory response. 
Furthermore, soluble AGEs activate monocytes. Inhibition of RAGEs in an accelerated 
atherosclerosis model in diabetes transgenic mice, completely suppresses vascular lesions, 
without changes in plasma lipid or glycemia (Schmidt, Yan et al. 1999). Elevated serum 
AGEs in patients with T2D were inversely correlated with the degree of endothelial-
dependent vasodilation in the brachial artery as measured by high resolution vascular 
ultrasound (Tan, Chow et al. 2002).  
 
III-5.3.3 The polyol route 
Glucose metabolism is activated by high intracellular glucose concentrations. First 
aldose reductase, which normally has the function of reducing toxic aldehydes to inactive 
alcohols, reduces glucose to sorbitol using NADPH as a cofactor, sorbitol is then metabolized 
to fructose by sorbitol dehydrogenase that uses NAD + as a cofactor. Sorbitol is a highly 
hydrophilic polyhydroxylated alcohol that accumulates in the cytosol with osmotic 
consequences that modify the intracellular tonicity by production of intracellular osmolytes to 
counterbalance the extracellular hypertonicity. The fructose produced by the polyol route is 
phosphorylated to fructose-3-phosphate then decomposed into 3-deoxyglucosone, a powerful 
glycosylating agent that enters the AGEs formation pathway. Finally, Consumption of 
NADPH by the aldose reductase limits its availability for the glutathione reductase, an 
enzyme that regenerates reduced glutathione, a critical antioxidant. 
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III-5.3.4 Activation of protein kinase C by diacylglycerol 
PKC plays an important role in endothelial dysfunction (Hink, Li et al. 2001, 
Cosentino, Eto et al. 2003). It induces the production of ROS by stimulating NADPH oxidase. 
The treatment of ECs and aortic SMCs with phorbol myristic acid (PMA), a PKC activator, 
increases the production of ROS that is reversed by diphenylene iodonium, an inhibitor of 
NADPH oxidase (Inoguchi, Li et al. 2000). Hyperglycemia causes vascular accumulation of 
DAG, Diacylglycerol, the physiological activator of PKC, thereby contributing to 
cardiovascular pathologies related to diabetes (Geraldes and King 2010). High levels of DAG 
have been found in the aorta and heart of diabetic rats (Inoguchi, Battan et al. 1992). 
Exposure of ECs and aortic SMCs to elevated glucose levels increases DAG levels and ROS 
production that is inhibited by GF109203X, a specific inhibitor of PKC (Inoguchi, Li et al. 
2000) thereby testifying to the central role of PKC in response to high glucose. Indeed, oral 
intake of LY333531, an oral inhibitor of PKCβ, improves the glomerular filtration rate, and 
retinal circulation in diabetic rats (Ishii, Jirousek et al. 1996). In humans, Chererithrin, another 
PKC inhibitor, reduced superoxide production by 25% in the internal mammary artery 
segments of non-diabetic patients compared to a significantly 60% reduction in diabetic 
patients, suggesting that inhibition of PKC decreases vascular ROS production in vessels 
from diabetic patients. 
 
III-5.3.5 The hexosamine pathway 
When the intracellular glucose concentration is high, it is metabolized by glycolysis to 
glucose-6-phosphate, then to fructose-6-phosphate before entering the glycolytic pathway. 
However, part of fructose-6-phosphate is diverted to another signaling pathway and converted 
to glucosamine-6-phosphate by the Glutamine Fructose-6 Phosphate Amidotransferase 
(GFAT) that further promotes the synthesis of uridine diphosphate-N-acetylhexosamine 
(UDP-GlcNAc), a substrate for N- or O-glucosamination of many proteins and transcription 
factor.    
Substantial evidence indicates that hyperglycemia-induced ROS production can promote 
telomere shortening, DNA damage, and trigger a p53-dependent response. Indeed, 
hyperglycemia in diabetic patients has been shown to be a crucial factor in accelerating the 
progression of endothelial senescence. (see chapter IV) 
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Chapter Four 
Endothelium Senescence and vascular function 
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IV-1 Cellular senescence 
Cell senescence was first defined by Leonard Hayflick in 1961who evidenced that 
fibroblasts stopped proliferating after a number of cell divisions (Hayflick and Moorhead 
1961). The number of cycles performed by the cell before discontinuation of the division was 
called "Hayflick Limit" and marked the onset of cell aging or senescence, thereby 
determining the lifespan.  
Senescence is defined as the physiological process of biological aging, associated with the 
progressive degradation of an organism's functions, caused by the accumulation of 
dysfunctional cells. Aging itself is not a disease, death occurring rather from pathological 
complications associated to ageing rather tat ageing itself because the renewal of tissues is 
essential to the viability of the body. Senescence is recognized as a potent tumor suppressor a 
mechanism that stops the proliferation of cells at risk of malignant transformation making of 
senescence a strong barrier against cancer progression (Vijg, Maslov et al. 2008). The 
ambivalence of senescence lies in the early benefit of tumor proliferation and the late 
deleterious effect related to aging, this duality is called antagonistic pleiotropy. 
At the cellular level, senescence is characterized by an irreversible cell cycle arrest leading to 
a non-proliferation state accompanied by a set of modifications, at the level of the 
morphological, functional, and gene expression level. 
 
IV-1.1 Characteristics of senescent cells 
Although senescent cells are metabolically active, their arrest in the G1 phase of the 
cell cycle has many consequences. From a morphological point of view, the senescent cells 
flatten out and their cell volume increases. Increased protein synthesis via the mTOR-
dependent signalling has been proposed to explain these changes (Fingar, Salama et al. 2002, 
Mamane, Petroulakis et al. 2006). Others suggested changes in the structure of the 
cytoskeleton (Nishio, Inoue et al. 2001).  
A common feature to senescent cells is the increase in the number and activity of lysosomes. 
This characteristic is at the origin of the increased β-galactosidase activity associated with 
senescence (SA-β-gal). Indeed, it has been shown that senescent cells express detectable β-
galactosidase activity at pH 6.0 that is different from the acidic β-galactosidase activity 
present in normal cells and detectable at pH 4.0 (Debacq-Chainiaux, Erusalimsky et al. 2009).  
Senescent cells exhibit excessive gene expression resulting in a secretion profile of many pro-
inflammatory cytokines, chemokines, growth factors, and proteases called the senescence-
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associated secretory phenotype (SASP). SASP confers a strong ability to senescent cells to 
interact with their environment, to promote and enhance inflammation, which plays a major 
role in age-related diseases such as atherosclerosis (Chung, Cesari et al. 2009, Sikora, Arendt 
et al. 2011).  
In addition, some SASP proteins may favour cell cycle arrest, and the secretion of including 
inflammatory cytokines (interleukins) and chemokines (Kuilman, Michaloglou et al. 2008).  
At the nuclear level, the structure of chromatin determines whether the gene is 
transcriptionally active (euchromatin) or silent (heterochromatin). Senescent cells have a 
characteristic foci of condensed heterochromatin, termed SAHF (senescence-associated 
heterochromatin foci) (Narita, Nunez et al. 2003) that are detectable as clusters after DAPI 
labelling of the DNA and are distinct from the homogeneous staining in non-senescent cells. 
Because the heterochromatin structure mainly depends on histone modifications by 
acetylation or methylation, acetylation of lysine 9 or methylation of lysine 4 of histone H3K9, 
is an exclusive marker of SAHF. SAHFs are associated with the down regulation of  genes 
regulated by the E2F transcription factor, such as cyclins, and to the occurrence of several 
pathways involving p16 or p53 proteins.  
It should be noted that many concepts related to senescence have been developed from studies 
of human fibroblasts and some immortalized cell lines. Therefore, their relevance should be 
questioned for primary endothelial cells. 
 
 
Figure 14: Characteristics of senescent cells. Senescent cells are flattened, they secrete 
inflammatory mediators, present DNA damages and high Senescent-associated ß 
galactosidase activity. They are maintained in G1 phase and are dysfunctional. 
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IV-1.2 Mechanisms of senescence 
IV-1.2.1 Replicative senescence 
Replicative senescence is observed after a number of divisions (Erusalimsky and 
Skene 2009) and is associated with physiological aging and would be triggered by the 
progressive shortening of telomeres, a DNA sequence located at the end of chromosomes, and 
by a dysfunctional telomerase. Indeed, the cells lose between 50 to 300 nucleotides telomeric 
after each division (Levy, Allsopp et al. 1992, Allsopp, Chang et al. 1995), until critical 
length, which triggers cell cycle arrest. Due to a defect in the DNA replication machinery, the 
so-called "end replication problem", conventional DNA polymerases are unable to replicate 
the end of the distal DNA strand, resulting in a gradual loss of nucleotides at the telomeres. 
This observation is at the origin of the hypothesis of the "mitotic clock".   
The telomeres consist of the same six nucleotides repeat sequence (TTAGGG) that 
extends over a length of 10 to 15 kilobases. The single-stranded 3 'end of the distal strand is 
inserted into the double-stranded DNA molecule at the telomere level, forming a T-loop 
which no longer allows the outgoing single-strand end to appear, thus preventing its 
recognition as a break, by the machinery of DNA repair, which can lead to cell death. This 
conformation is stabilized by a set of specialized binding proteins called shelterin, a 
heterodimeric complex of six proteins, TRF1, TRF2, Pot1-TPP1, Rap1, and Tin2. The 
synthesis of telomeric DNA requires the presence of a particular DNA polymerase, a 
telomerase, a ribonucleoprotein complex consisting of an enzymatic subunit, hTERT 
(catalytic subunit of human telomerase reverse transcriptase) which catalyzes the addition of 
the TTAGGG sequence to the 3 'end of the DNA by virtue of its reverse transcriptase activity 
using a RNA primer present in the regulatory subunit, hTERC (Blackburn 2000, McEachern, 
Krauskopf et al. 2000). The majority of somatic cells have a very low level of telomerase, 
unlike germ cells or tumor cells. The inhibition of telomerase by RNAi induces the arrest of 
tumor growth (Li, Crothers et al. 2005). In contrast, overexpression of telomerase in mice 
increases their life expectancy (Gonzalez-Suarez, Samper et al. 2001). 
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 Figure 15 : Mechanism of telomer repair The shortening of telomeres induces 
senescence (Herrera, Mingorance et al. 2010). (DDR: DNA damage response, ATM: ataxia 
telangiectasia mutated, ATR: ATM and Rad3-related 
 
 
IV-1.2.2 Premature senescence 
Other studies have reported that the same cells able to enter replicative senescence after a 
certain number of divisions, could also present senescence, despite a small number of cell 
divisions, suggesting the existence of other inducers of senescence independently shortening 
of telomeres. Telomer extension by telomerase overexpression in human fibroblasts has been 
reported not to protect against senescence observed after exposure to UV, γ-irradiation, or 
H2O2, confirming the existence of a senescence mechanism independent of telomerase action 
(Gorbunova, Seluanov et al. 2002). Indeed premature senescence is also inducible in response 
to 2 different cellular stress (Erusalimsky 2009): Stress-Induced Premature Seniors (SIPS) 
including oxidative stress or DNA damage, and OIS (Oncogene-Induced Senescence) 
involving persistent mitogenic stimulation or exposure to radiation. 
The development of premature endothelial senescence in pathological conditions proves to be 
an early response to stress induced by various risk factors such as diabetes, hypertension, 
smoking or hyperglycemia. In fact, cardiovascular risk factors are associated with an increase 
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in oxidative stress levels (Csiszar, Ungvari et al. 2002). Thus, aortic fragments from 
spontaneously hypertensive rats (SHR) show an increase in SA-β-gal labeling, associated with 
an increase in phosphorylation of the γH2AX histone and overexpression of p53, compared to 
control rats Kyoto. Similarly, SA-β-gal labeling was observed in the thoracic aorta of Zucker's 
obese diabetic rats (ZDF) but remains undetectable in their lean counterparts (ZL) (Chen, 
Brodsky et al. 2002).  
The distinction between replicative senescence, induced by telomere shortening, or stress-
induced premature senescence remains delicate. It is very likely that both types of senescence 
may contribute jointly to pathological processes in vivo. Excessive telomere shortening has 
been observed in circulating white blood cells of patients with hypertension (Jeanclos, Schork 
et al. 2000), coronary atherosclerosis (Samani, Boultby et al. 2001, Fitzpatrick, Kronmal et al. 
2007), myocardial infarction (Brouilette, Singh et al. 2003), and diabetes (Jeanclos, Krolewski 
et al. 1998) suggesting that cardiovascular risk factors could also affect the replicative 
potential of cells in vivo, and accelerate the physiological aging process (Chen and 
Goligorsky 2006). It has been shown that premature senescence ECs from atherosclerotic 
patients exhibited the same pathways components than replicative senescence. This may be 
related to the fact that atherothrombosis is an inflammatory process characterized, among 
other things, by a so-called "restorative" hyperproliferation of ECs and CML, which can 
explain the shortening of telomeres observed in these cells. In addition, in atherosclerotic 
patients, the development of EC senescence correlates with the duration of exposure to 
cardiovascular risk factors and the severity of the disease rather than with age. 
Overexpression of telomerase in these cells stabilizes telomere length and slows the onset of 
senescence (Voghel, Thorin-Trescases et al. 2007).  
IV-1.3 Mechanisms of cell cycle arrest in senescence  
 When DNA damage is detected, the cell cycle is momentarily interrupted until 
repair or, if appropriate, entry into senescence or apoptosis. Both the replicative and 
premature senescence mechanisms often involve the p16/Rb or p53/p21 tumor suppressor 
pathway, which orchestrates cell cycle arrest. The p53 protein regulates apoptosis via the 
activation of the proapoptotic protein BAX (Miyashita and Reed 1995), and senescence via 
activation of the p21 cell cycle inhibitor (el-Deiry, Tokino et al. 1993). In response to 
shortening of the telomeres or after DNA damage, p53 is phosphorylated on the serine residue 
by the ATM, or on the serine residue by the CHK2 kinase (ATM and CHK2 being the 
proteins of the DDR: DNA Damage Response), which stabilizes p53 preventing its binding to 
its main inhibitor, mdm2. The ubiquitylation of p53 by mdm2 causes its degradation in the 
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proteasome. Moreover, the acetylation of p53 on the lysine residues 382 and 320 allows its 
binding to the DNA and increases its transcriptional activity allowing the overexpression of 
its main target gene in senescent cells, p21 / WAF1 (Webley, Bond et al. 2000), see figure 15. 
 The p21 protein is a Cip / Kip family cyclin dependent kinase inhibitor, it binds to the cyclin 
kinase CDK2, preventing the formation of the cyclin E-CDK2 complex and the G1-S 
transition (Harper, Adami et al. 1993), see figure 16 below. CDKs are serine-threonine 
kinases, while cyclins lack enzymatic activity and serve as a regulatory subunit for CDKs. 
The cell enters and leaves the cell cycle according to the balance between synthesis and 
degradation of cyclins, whose synthesis is not constant. Inhibition of these complexes results 
in cell cycle arrest. 
 
 
Figure 16 : Cell cycle regulation by the complex Cyclin Dependent Kinase- Cyclin 
Control points of the cell cycle are regulated by specific cyclin-CDK (cyclin-dependent 
kinase) complexes. CDKs are serine-threonine kinases, while cyclins lack enzymatic activity 
and serve as a regulatory subunit for CDKs. The cell enters and leaves the cell cycle 
according to the balance between synthesis and degradation of cyclins, whose synthesis is not 
constant. Inhibition of these complexes results in cell cycle arrest. CDK inhibitors, CKIs, are 
divided into INK4 and the Cip / Kip families. During phase G1, an important target of cyclin-
CDK complexes is the retinoblastoma protein (Rb). In its dephosphorylated active form, it 
forms a complex with the transcription factor E2F and repress the expression of many genes 
involved in the regulation of the cycle. Phosphorylation of Rb releases the E2F transcription 
factor which binds to the promoters of different genes involved in the progression of the cycle 
and allows the entry into mitosis (Schafer 1998).  
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 The p16 protein is a CDK inhibitor involved in senescence. Overexpression of p16 
occurs after p21 activation and proliferation arrest, emphasizing the essential role of p21 in 
the initiation of senescence (Alcorta, Xiong et al. 1996, Stein, Drullinger et al. 1999, Dulic, 
Beney et al. 2000). p16 belongs to the INK4a family. It interacts with CDK4 and CDK6 to 
induce cell cycle arrest in G1 phase, dependent on Rb protein (Parry, Bates et al. 1995). 
Unlike p21, p16 is not under the control of p53. It is regulated by the RAS-RAF-MEK 
pathway. 
There is also a debate about the need and contribution of each of the tumor suppressor 
pathways to initiate senescence. In human fibroblasts both pathways can be involved (Itahana, 
Zou et al. 2003). It has been proposed that separate senescence programs may progress in 
parallel, resulting in "mosaic cultures," with some cells expressing p21 or other p16s or both 
(Ben-Porath and Weinberg 2005).  
 
IV-2 Contribution of cellular senescence to vascular aging 
 Many studies confirm an association between aging-related pathologies and 
mediators of cellular senescence. Clearance of p16-positive senescent cells, using a transgene, 
INK-ATTAC, to induce apoptosis of cells expressing p16, prolonged the life span of mice, 
and attenuated age-related deterioration of several organs such as kidney, heart and adipocytes 
(Baker, Smyth et al. 2014).  
Several research groups have examined in vivo the hypothesis that vascular cell senescence 
may contribute to the pathogenesis of cardiovascular disease (Burrig 1991) notably using  
cytochemical analysis SA β-gal. In animals, an increase in the number of SA-β-gal positive 
cells with overexpression of p53, p21 and p16 and high oxidative stress was observed in the 
aortic endothelium of obese and diabetic Zucker rats (Chen, Brodsky et al. 2002, Brodsky, 
Gealekman et al. 2004). In addition, Fenton et al. detected positive SA-β-gal endothelial cells 
in rabbit carotid arteries after repeated balloon endothelial denudation. All of these studies 
confirm the existence of endothelial senescence in vivo and its contribution to the 
pathogenesis of cardiovascular diseases (Fenton, Barker et al. 2001, Minamino, Miyauchi et 
al. 2002).  
Histological examination of human atherosclerotic plaques confirmed the presence of SA-β-
gal-positive ECs and smooth muscle cells, that also showed overexpression of p53, p21 and 
p16 and short telomeres. In addition, senescent endothelial cells have also been identified in 
coronary arteries of patients with ischemic heart disease, whereas no SA-β-gal positive cells 
have been observed in the internal mammary arteries of the same patients (Minamino, 
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Miyauchi et al. 2002), highlighting a role of the endothelial territory and the existence of 
possible areas at risk of senescence. In another study, the accumulation of senescent 
cardiomyocytes with significant telomere shortening was detected by endomyocardial biopsy 
in the hearts of elderly patients with cardiomyopathy (Chimenti, Kajstura et al. 2003).  
 
IV-2.1 Senescence and endothelial dysfunction 
Whatever the origin of the senescence (replicative or premature), the resulting 
functional alterations, lead to a pro-inflammatory and pro-thrombotic phenotype, known to 
have a role in the cardiovascular diseases associated with aging and associated disorders like 
diabetes or hypertension. 
Several studies have confirmed the role of senescence in the development of endothelial 
dysfunction. Basal NO production by human umbilical vein endothelial cells (HUVEC) 
decreases with the doubling of the population (Sato, Kaji et al. 1993). Similarly, NO 
production in response to shear forces is also decreased in senescent human aortic endothelial 
cells (HAEC) (Matsushita, Chang et al. 2001). In addition, production of prostacyclin is also 
decreased in EC after several serial passages (replicative senescence), or after incubation with 
H2O2 (premature senescence), while thromboxane A2 production is increased. One study has 
shown by a more direct approach that targeted p53 overexpression in the endothelium is 
associated with decreased endothelium-dependent relaxation in aortic rings, with reduced NO 
bioavailability, whereas sodium nitroprusside, a NO donor, could trigger relaxation. The role 
of senescence in the induction of endothelial dysfunction has been confirmed by other 
approaches showing that the prevention of senescence improves endothelial dysfunction. 
Indeed, the extension of telomeres by ectopic expression of hTERT (catalytic subunit of 
telomerase) in human ECs in culture, prolonged their lifespan and protected against 
endothelial dysfunction (Yang, Chang et al. 1999, Minamino, Miyauchi et al. 2004). 
Similarly, transfection of human aortic EC by telomerase induced a young phenotype, delayed 
age-related deficits in eNOS expression, and increased NO production (Matsushita, Chang et 
al. 2001).  
 
IV-2.2 Oxidative stress at the origin of endothelial senescence 
The theory of free radical contribution to aging dates back to the middle of the 20th century, 
when it was discovered that ROS, traditionally considered too reactive to exist in biological 
systems, can be formed in situ, in response to ionizing radiation, or oxygen, and are 
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responsible for deleterious responses. Harman proposed that ROS be endogenously formed 
from oxygen metabolism and play a vital role in the aging process (Harman 1956). 
Kapahi et al. Observed a direct correlation between the longevity of different animal species 
and their antioxidant defenses (Kapahi, Boulton et al. 1999). However, most clinical trials 
have failed to demonstrate any significant beneficial effect of antioxidants (α-tocopherol, 
vitamin C and / or E) on the morbidity and mortality associated with cardiovascular disease 
(Steinberg and Witztum 2002).  
Numerous in vitro experimental data indicate that oxidative stress induces senescence 
following oxidative damage to DNA. Thus, the oxidation rate of the DNA measured by the 
release of 8-dihydroxyguanine is increased in senescent cells (Chen, Brodsky et al. 2002). 
Oxidative stress increases telomere shortening (von Zglinicki, Pilger et al. 2000), probably 
because of the particular richness of telomer DNA, in guanidic bases particularly vulnerable 
to oxidation. 
The culturing of human CML in a hypoxic environment prolongs their lifespan and increases 
the activity of telomerase, compared to those cultivated under normoxic conditions 
(Minamino and Komuro 2002). Furthermore, the addition of an antioxidant, N-acetyl cysteine 
(NAC) in the culture medium, prevents the replicative senescence of primary coronary pork 
CEs (Khemais-Benkhiat, Idris-Khodja et al. 2016). Similarly, NAC significantly delays 
senescence in isolated arterial segments from patients with severe coronary artery disease, 
activates the telomerase catalytic subunit (hTERT), and inhibits telomere attrition (Voghel, 
Thorin-Trescases et al. 2007).  
Conversely, culturing smooth muscle cells of rat thoracic aortas under hyperoxic conditions 
(40% O2) induces DNA damage and up-regulates markers of senescence. Hyperoxia causes 
accelerated shortening of telomeres (66 base pairs lost at 20% O2 versus 486 base pairs at 
40% O2), accompanied by p53 activation and premature senescence (Vaziri, West et al. 
1997).  
In fact, the senescence induced by the oxidative stress constitutes a model of accelerated or 
premature senescence frequently used. Chronic exposure of human umbilical vein endothelial 
cells (HUVEC) to non-cytotoxic doses of hydrogen peroxide or to an inhibitor of glutathione 
synthesis, buthionine sulfoximine, accelerates the onset of senescence after 30 versus 46 
doublings of population (Kurz, Decary et al. 2004). Similarly, the exposure of ECs of porcine 
coronary arteries to oxygen peroxide (H2O2) increases SA-β-galactosidase activity and 
accelerates the onset of expression of cell cycle inhibitors (Abbas, Jesel et al. 2017). 
Symmetrically, reducing the activity of intracellular peroxides with a scavenger, alpha-
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phenyl-t-butyl-nitrone, reduces the degree of telomere shortening and increases cell lifespan 
(von Zglinicki, Pilger et al. 2000).  
 
IV-2.3 Role of the Angiotensin System in vascular senescence 
Benigni et al. have shown that inactivation of the Ang II AT-1 receptor increases longevity in 
mice. When all wild-type mice died, 85% of AT-1R KO mice were still alive (Benigni, Corna 
et al. 2009) suggesting that the angiotensin system plays a key role in the aging process itself. 
The components of the renin-angiotensin system have been shown to be increased in the 
tissues of older animals (Wang, Takagi et al. 2003), and inhibition of RAS by sartans or ACE 
inhibitors, shows a protective effect against age-related vascular diseases in rodents, such as 
hypertension and atherosclerosis (de Cavanagh, Piotrkowski et al. 2004, Basso, Paglia et al. 
2005), and limits the development of age-related cardiovascular disease in humans (Brown 
and Hall 2005).  
Ang II is indeed likely to contribute to age-related vascular diseases such as atherosclerosis by 
promoting the senescence of SMCs and ECs (Kunieda, Minamino et al. 2006, Shan, Guo et al. 
2014).  
Herbert et al. demonstrated that Ang II induces senescence of human SMCs in response to 
DNA damage caused by ROS. This response involved both replicative and premature 
pathways of senescence as this induction was associated with telomere shortening, however, 
transfection of SMC by the hTERT subunit of telomerase was not sufficient to prevent 
induced senescence by Ang II. Only pre-incubation of cells with Losartan, an AT-1R 
antagonist, or catalase, an antioxidant, prevented Ang II-induced senescence and associated 
DNA damage (Herbert, Mistry et al. 2008). These results suggest that Ang II, via the AT-1R 
receptor and the production of ROS, causes DNA damage in SMCs that cause cell cycle arrest 
and senescence. In vitro, Ang II decreases the telomerase activity of endothelial progenitor 
cells, an effect that is prevented by superoxide dismutase, again suggesting the involvement 
of oxidative stress (Imanishi, Hano et al. 2005).  
Several molecular mechanisms have been proposed to explain the induction of vascular 
senescence by Ang II. The stimulation of endothelial progenitor cells by Ang II increases the 
expression of the gp91phox subunit of NADPH oxidase, thus contributing to oxidative stress, 
as evidenced by the formation of peroxynitrite (Imanishi, Hano et al. 2005). Exposure of 
human umbilical vein endothelial cells (HUVEC) to Ang II induces senescence via the 
production of mitochondrial ROS released by loss of mitochondrial membrane potential 
(ΔΨm) and membrane redistribution of cytochrome C. These mitochondrial effects are 
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prevented by benazepril, a converting enzyme inhibitor or Losartan. Symmetrically, HUVEC 
treatment by a mitochondrial transition pore activator (mPTP), carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) induces mitochondrial damage similar to that induced by 
Ang II, accompanied by an increase in markers of senescence. However, these effects are not 
prevented by benazepril or Losartan, confirming the role of mitochondrial damage in the 
induction of senescence by Ang II in HUVECs. 
In addition to the induction of oxidative stress, Ang II disrupts the intracellular redox-
sensitive balance by decreasing antioxidant defenses. Ang II down-regulates the expression of 
catalase by preventing the binding of the FoxO1 transcription factor (forkhead box O1) to the 
promoter of the catalase gene (Xiong, Salazar et al. 2010). 
Other actors and molecular mechanisms are involved in senescence in response to Ang II such 
as activation of small G Ras proteins, MAPKs, and transcription factors such as the nuclear 
factor NF-kB and AP-1 were also described (Blagosklonny 2003).  
 
IV-2.4 Hyperglycemia and endothelial senescence 
Recently, the arguments have multiplied in favor of the involvement of endothelial 
senescence as an early event of diabetes-related endothelial dysfunction. Senescence has been 
described in diabetic rat vessels and in ECs exposed to high concentrations of glucose (Yokoi, 
Fukuo et al. 2006, Bhatt, Lim et al. 2013). An increase in SA-β-gal activity was observed in 
the ECs of the aorta of mice made diabetic treated by streptozotocin , and in the aorta of 
Zucker diabetic rats (Inoguchi, Li et al. 2000, Yokoi, Fukuo et al. 2006). 
In diabetic patients, measurement of leukocyte telomeres has been used as a surrogate for 
vascular senescence. The telomere length was  significantly shorter in type 2 diabetics 
compared to control subjects, and inversely proportional to levels of oxidative DNA damage 
(Sampson, Winterbone et al. 2006).  
In vitro, many teams have shown an induction of endothelial senescence by "high glucose in 
the incubation media. Hayashi et al., showed that exposure of HUVECs to high glucose 
concentrations increases SA-β-gal activity and ROS production, and decreases telomerase 
activity. These effects were accompanied by decreased expression of eNOS and endothelial 
NO production. All of these effects are prevented by treatment with L-arginine, L-citrulline 
and antioxidants (vitamin C and E) alone or in combination, as well as by overexpression of 
eNOS in transfected ECs, suggesting an important role for NO in the prevention of 
endothelial senescence during diabetes (Hayashi, Matsui-Hirai et al. 2006).  
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Interestingly, the young endothelial cells cultured on a glycated collagen matrix show an 
increase in SA-β-gal activity and the expression of p53 without telomere shortening nor a 
decrease in telomerase activity. These effects are associated with a decrease in NO production 
despite a 3-fold increase in eNOS expression, and an increase in nitrotyrosine-modified 
proteins. All these effects are prevented and reversed by the antioxidant treatment, ebselen or 
by a superoxide dismutase analogue. These results indicate that the reduction in the 
bioavailability of NO, the excess of peroxynitrite and / or superoxide anions observed in 
diabetes are the cause of premature endothelial senescence induced by hyperglycemia (Chen, 
Brodsky et al. 2002).  
Meta-analysis of several clinical trials showed that inhibition of RAS decreased the number of 
new diabetic patients (Abuissa, Jones et al. 2005, Yusuf, Ostergren et al. 2005). In addition, 
clinical trials have shown a beneficial CV effect of ACE inhibitors and Sartans in diabetics. 
Thus, it is possible that the angiotensin system is involved in the development of vascular 
dysfunction during diabetes. 
 
IV-2.4.1 Role of the angiotensin system in senescence induced by hyperglycemia 
Chen et al., Showed that EC exposure to high glucose (HG) increases SA-β-gal activity and 
mitochondrial oxidative stress, accompanied by overexpression of the conversion enzyme, 
and AT-receptor. 1 of Ang II. The treatment of ECs with ACE inhibitors (benazepril) or 
Sartans (losartan) inhibits HG-induced senescence and mitochondrial oxidative stress, 
suggesting a key role of the RAS system in glucose-induced endothelial senescence (S. 
Khemais, 2016). Thus, the deleterious effects of chronic hyperglycemia on vascular function 
could contribute to the development of cardiovascular disease (CVD) in diabetics via 
exaggerated AT1 –dependent senescence. 
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Hypothesis and aims 
Because MPs are markers of vascular damage occurring during acute events such as 
myocardial infarction, but also identified during other chronic disorders with cardiovascular 
issues such as diabetes, we reasoned that  
 
Ø Microparticles contribute to the endothelial senescence and consecutive 
dysfunction in vascular aging 
Ø Microparticles contribute to the premature endothelial dysfunction in diabetes 
Ø Endothelial pharmacological protection against premature senescence or dysfunction 
should prevent MP-induced vascular damage 
 
To explore these hypothesis our aims were: 
 
§ To set and validate a methodological approach for the isolation of tissue MPs as a 
source of immune cells-derived MPs or of coronary artery-derived MPs 
§ To measure the endothelial pro-senescent properties of these MPs  
§ To measure the properties of these MPs on endothelial-dependent vascular 
reactivity  
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Results 
Results Part 1: 
Methodological approach to the study of tissue MPs:  
MPs from splenocytes as a signature of the immune cells 
activation and vascular effectors  
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1-Background and proof of concept 
One of the most recognized results of aging is reduced immune function (Thompson, 
Shay et al. 2003). The effects of aging on the immune system are widespread and affect the 
rate at which naive B and T cells are produced the composition and quality of the mature 
lymphocyte pool (Thompson, Shay et al. 2003). 
In healthy individuals, leukocyte-derived MPs (LMPs) represent a small fraction (<10%) of 
the total MP population in blood (Hoyer, Nickenig et al. 2010). Plasma levels of LMPs 
significantly raise in patients with cardiovascular, atherosclerosis, hypertension, and diabetes 
mellitus (Owens and Mackman 2011, Angelillo-Scherrer 2012).  
Few studies is septic rats have indeed shown that circulating circulating leukocyte-derived 
MPs are elevated and a characteristic feature of a pro-inflammatory and procoagulant state. 
(Mostefai, Agouni et al. 2008, Boisrame-Helms, Delabranche et al. 2014) In patients with 
septic shock, elevated MPs of neutrophile and endothelial origin typify underlying 
disseminated intravascular coagulation and patients outcome may be related to the Netosis, 
i.e. to the proportion of neutrophils that have release decondensed chromatin to limit bacterial 
spread.(Delabranche, Stiel et al. 2017) 
Although circulating MPs of leukocyte origin are a signature of the pro-inflammatory 
and procoagulant vascular response, their properties as vascular effectors remain difficult to 
study in animal models owing to technical limitations: the purification yields from the plasma 
remain low in order to avoid exosome contamination, their half-life is not well characterized 
and varies with species and pathological condition, making the identification of the smallest 
proportion of leukocyte-derived MPs, such as neutrophil-derived MP, difficult to assess.    
To circumvent this difficulty, we chose to harvest immune MPs from the spleen of 
rats. The methods offer the advantage of a possible assessment of a pharmacological control 
of the MP release by various treatments targeting either plasma membrane remodelling or 
specific leukocyte sub-population. To validate the model, we compared the release of MPs 
generated from splenocytes, under conditions mimicking innate or adaptive immune 
responses and studied their variations with ageing. The method is based on the harvest of rat 
spleen tissues that were submitted to standardized extraction procedures to obtain spleen–
derived leukocytes. After a first osmotic elimination of red blood cells, splenocytes were 
cultured for 24h before collection of MPs in the cell supernatants.  
To assess the ability of splenocytes to release SR-MPs we compared the amount and 
properties of MPs generated at baseline or after stimulation by E. Coli LPS or by a 
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combination of calcium ionophore and PMA to mimic innate and adaptative immune response 
triggered by LPS or PKC-dependent pathways. This method was previously developed in the 
laboratory by Ali El Habhab and Sonia Khemais (thesis in 2018 and 2017).  In addition, Ali 
El Habhab demonstrated that SR-MPs are inducers of endothelial senescence without 
triggering EC apoptosis. 
Other members of the laboratory have investigated the MP release from the vessel 
wall. All data will be compiled to publish a methodological approach for the analysis of tissue 
MPs, an area of expertise that remains to be developed. The manuscript of compiled data is in 
preparation with co-authors (see annexes and discussion)  
 
2- Methodological approach 
Previous data from our group and others have shown that circulating vascular MPs 
levels remain stable in middle age rats whereas onset of pancreatic islets damage could be 
observed in histological sections, suggesting that early age-related organ alterations may be 
specific and hardly detectable in blood flow. (Faggioli, Wang et al. 2012)  
In a first set of experiments and to validate the method, we examined the variations of 
splenocyte-derived MPs (SR-MPs) obtained from splenocytes freshly isolated from the spleen 
of young, middle age and old Wistar rats.  
 
In a second set of experiments the method was optimized and was further applied to 
the study of the interactions between leukocyte MPs and endothelial cells in a model of high 
glucose-induced endothelial senescence, in order to further examine whether high glucose 
concentration could potentiate the pro-senescent effect of SR-MPs. Endothelial-dependent 
vascular response to high glucose and SR-MPs was also assessed.  Data are summarized in an 
original manuscript 
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2-1- Variations of splenocyte-derived MPs (SR-MPs) with age and stimulus 
Spleens were isolated from young, middle-age and old Wistar rats (8, 24, 72 weeks, 
respectively). After osmotic treatment to eliminate red blood cells, 3 millions splenocytes/ mL 
were seeded in RPMI culture medium in the absence or presence of 5 µg/ml LPS from E. 
Coli, or a combination of PMA (25 ng/ml / 1 µM A23189 calcium ionophore (PMA/I), see 
following manuscript). 
 
2-1.1 Ageing and LPS or PMA/I treatment reduce splenocyte recovery 
After 24h incubation of splenocytes in culture medium, a reduced recovery of 
splenocytes from old or middle age rats vs. young rats with respectively 14.4 %, 31.83%, 
62.04% loss (see figure below). Whatever the age, both inducers led to a significantly reduced 
recovery of splenocytes (untreated cells from young rats: 14.4 % loss vs. 25.4 % after 24h 
treatment with LPS and 42.08% by the combination PMA/ A23189 calcium ionophore 
(PMA/I); middle-age rats untreated cells: 31.83 % loss vs. + LPS: 43.2%, + PMA/I :, 61.01% 
; old rats untreated cells : 62.04% loss vs. + LPS: 85.52% , + PMA/I : 72.03%). 
 
 
Figure 1. Effect of age, LPS or PMA/calcium ionophore treatment on the splenocyte 
recovery.  CTL: unstimulated splenocytes 
  
2-1.2 Ageing and LPS or PMA/I treatment promote the release of SR-MPs 
Compared to young rat cells, splenocytes from middle age and old rats release a significant 
higher amount of SR-MPs after 24h culture (2- and 3.5 – fold enhancement respectively). 
Whatever the age, LPS or PMA/I) enhanced significantly the SR-MP release 
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(approximatively 1,3 and 2- fold enhancement by LPS or PMA/I respectively in young or 
middle age rats, and 2.8 enhancement by PMA/I in cells from old rats).   
 
 
Figure 2. Effect of age, LPS or PMA/calcium ionophore treatment on the release of 
MPs by splenocytes 
 
2-2 Ageing and LPS or PMA/I treatment modify the pro-senescent effects of SR-MPs 
To determine whether the properties of SR-MPs vary with age, SR-MPs were isolated 
from the spleens, cultured in medium for 24h as above, isolated from supernatant before 
incubation with porcine primary coronary endothelial cells. All MP preparations were applied 
at the identical concentration (10 nM). After 48h, senescence was measured in ECs by the 
ability of Senescence-Associated galactosidase to cleave a fluorogenic substrate (figure 3).  
 
Figure 3. Impact of the age on SR-MPs induced endothelial senescence. Senescence was 
measured by flow cytometry using the FDG fluorogenic substrate of senescence-associated -β 
galactosidase (SA- β Gal activity). –FDG: unlabelled ECs, + FDG: labelled ECs. SMPCTL: 
SR-MPs isolated from the spleen without any inducer of MP release 
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Taken together, these data indicate that SR-MPs are indicators of the spleen 
tissue damage:  
 
Ø The ability of splenocytes to release SR-MPs decreases with age 
Ø SR-MP release in response to LPS and PMA/I is higher than baseline  
Ø SR-MPs acquire significant endothelial pro-senescent property with age 
 
 
2-3 High glucose concentration modify the ability of splenocytes to shed MPs  
As shown in the   figure below a concentration of 5 millions splenocytes /mL induces 
a drop of the medium glucose concentration as early as 5 hours after splenocyte culture in 
RPMI medium containing 11 mM glucose (normal glucose, NG) or 10h in RPMI containing 
25 mM glucose (high glucose, HG). Therefore, we selected 3 millions/mL splenocytes to 
produce MPs in both HG and NG culture media in order to limit glucotoxicity that might alter 
the number and/or properties of a proportion of the released MPs.  
 
Figure 4. Kinetics of glucose consumption by splenocytes incubated in high (HG) and 
low glucose (LG) over 24 h. Cells were incubated at different concentrations 
 
To further confirm that SR-MP shedding from splenocytes is dependent on their environment, 
we incubated 5 million/mL splenocytes in NG or HG for 30 min and extracted the MPs after 
additional 20 min (17 rpm, RT) rotating of the cell suspension, before application of the 
standardized centrifugation isolation procedure (800g, and twice 14000 g). 
Early discrepancy between the two media was evidenced after a total exposure of 40 min.  
Compared to NG, HG led to a significant increase in MP shedding that mirrored a drop of 
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splenocyte recovery. However, the enhancement did not the optimal effect obtained by 
treatment with a combination of phorbol myristate acetate and calcium ionophore (PMA/I) 
 
 
 
 
 
 
 
 
Figure 5. Early alteration of splenocyte recovery and MP shedding in high (HG) and low 
glucose (LG). Measurements were performed after 40 min incubation and compared to 
stimulation by a combination of phorbol myristate acetate and calcium ionophore known to 
prompt optimal SMP release. 
 
 
These data confirm that spleen-derived MPs are reliable indicators of the 
severity of the alterations of membrane remodelling: 
Ø SR-MP shedding is enhanced in response to exogenous pro-
inflammatory mediators (PMA/I) and in the presence of high glucose 
concentration.  
Ø Alterations of SR-MP shedding prompted by exogenous mediators 
are initiated within the first hour of incubation.  
  
Having optimized the conditions of MP generation from splenocytes and their isolation, 
we took advantage of this important source of MPs derived from primary immune cells to 
study their effector properties in hyperglycemia-induced endothelial senescence. 
 
3- Impact of short and long term incubation for the investigation of SR-MP vascular 
effects: Preliminary studies with coronary artery rings  
We had to optimize the classical vascular reactivity study procedures in order to be able to 
investigate MP effects, owing to the mandatory longer time of incubation. In preliminary data 
we measured bradykinin-induced relaxation after 6h, 12h, 18h, and 24h incubation in RPMI 
containing 11 mM glucose. Data indicate that under our conditions of incubation (37°C, 
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sterile and humide atmosphere), vascular relaxation is achieved at lower bradykinin 
concentration. Because the relaxation response was sharp we applied a progressive bradykinin 
concentration between 10-10 M- 7.1 10-9 M. (see figure 5 bis below)  
RPMI was selected because other tested media like MCDB led to higher variability in 
relaxation values. Similarly, supplementation of media with foetal bovine serum (10 % in 
RPMI or 15% in MCDB) led to higher variability in vascular relaxation. To circumvent this 
drawback the optimal incubation procedure included RPMI without serum and a gentle hand 
shaking of the incubation plate, every 3 hours. 
 
Figure 5bis. Effect of incubation time on the endothelial-dependent relaxation of porcine 
coronary artery rings in response to bradykinin. Measurements were performed after 1h, 
15h and 22h of incubation in RPMI medium without serum at 37°C under humid atmosphere. 
Ablation of the endothelium before adding bradykinin completely abolished vasorelaxation. 
Green curve: control (no incubation at 37°C, rings were kept in Krebs solution at 4°C during 
the time of incubation of the other samples) 
 
4- Impact of glucose concentration for the investigation of SR-MP vascular effects: 
Preliminary studies with coronary artery rings 
Because glucose concentration might interfere with the endothelial-dependent relaxation, we 
examined whether glucose concentration could vary with the incubation time in the limited 
incubation volume of the microtitration wells. Glucose concentration was measured in 0.5 ml, 
1 mL, 5 mL RPMI after 1h, 6h, 12h, 18h, and 24 hours. We could observe that 1 mL 
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incubation medium lost 0.22 mM glucose per hour in the presence of 1 ring of porcine 
coronary artery (2-3 mm width) (see figure 5 ter below). For comparison purposes between 
high and low glucose concentrations, incubation media were ready-to-use in order to avoid 
any modification of other reactants of the medium. Optimal incubation time was 18h (without 
MPs) that enabled clear differences between high and low glucose effects on the vascular 
response, either by vascular reactivity or by measuring protein expression (see also part 2). 
Finally, to avoid misinterpretation of the data, wells in which the incubation medium colour 
turned to yellow were suspected of contamination and discarded. However, it has to be noted 
that a switch of colour could also be observed after glucose shortage.  To prevent 
contamination, extensive washing of the ring prior incubation was performed either with 
RPMI or sterile Krebs buffer (4-5 times at room temperature and under the hood). 
 
Figure 5 ter. Kinetics of glucose consumption by the porcine coronary artery rings. 
Measurements were performed after 1h, 15h and 24h of incubation in RPMI medium 
containing 11 mM without serum at 37°C under humid atmosphere. Concentration was 
measured as mM of glucose in the culture medium (1 mL containing 1 ring 2-3 mm length) at 
each time. N=6 experiments, each measure performed in triplicate (6 different individuals).  
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High glucose potentiates the pro-senescent effect of leukocyte-derived 
MPs in isolated ECs and in the vessel wall: Impact on endothelial-
dependent control of the vascular tone  
 
 
Altamimy R, Qureshi A, Amoura L, El Habhab A, EL Itawi H, Kassem M, Khemais S, Pollet 
B, Zobairi F, Auger C, Schini-Kerth V, Toti F. 
 
 
Summary 
Introduction Microparticles (MPs) are plasma membrane vesicles and vascular effectors. We 
have shown that (i) leukocyte-derived MPs shed in response to stress are pro-inflammatory, 
procoagulant and prosenescent endothelial effectors, (ii) high glucose induces premature 
endothelial senescence. 
Objective: To determine the combined noxious effects of leukocyte-derived MPs endothelial 
and high glucose on endothelial senescence and dysfunction. 
Methods:  Leukocyte MPs were isolated from rat splenocytes with 5 mg/ml LPS (MPLPS), 25-
ng/ml PMA/1mM A23187 ionophore (MPPMAi), or vehicle (MPCTL). Porcine coronary artery 
endothelial cells (ECs) at passage 1 were incubated for 48 h with 1-30 nM MPs in high or low 
glucose concentration (HG 25 mM, NG 5.5 mM). Senescence-associated β-galactosidase 
(SA-ß-GAL) activity was assessed by C12FDG, protein expression by Western blot analysis. 
Pig coronary artery rings were pre-incubated with HG or NG for 12 h prior to addition of 1-30 
nM MPs for 12h. Bradykinin (BK)-induced endothelium-dependent relaxations were assessed 
in organ chambers, and staining of target proteins by confocal microscopy. 
Results: At 10 nM, MPLPS and MPPMA/I enhanced SA-ß -GAL activity both by about 2-fold in 
NG, and respectively 3 and 3.7-fold in HG. The expression of senescence markers p21, p16 
doubled and that of eNOS decreased 2-fold. MPPMAi and MPLPS induced a concentration-
dependent inhibition of BK-induced relaxation, inhibition by respectively 10 nM and 30 nM, 
being 65 % in NG, amounting to about 85% in HG, whereas 30 nM MPCTL had no effect. 
MPPMAi and MPLPS reduced eNOS expression by 60 % in NG and 80 % in HG. Conversely, 
VCAM-1, COX-2 was up regulated.  
Conclusion: Leukocyte-derived MPs enhance HG-induced alteration of the endothelial 
function by inducing premature senescence and might contribute to vascular dysfunction in 
diabetes patients. 
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Introduction 
The pathogenesis of atherosclerosis is highly accelerated by impaired glucose 
tolerance and diabetes. Insulin resistance can significantly contribute to early vascular 
dysfunction in patients with type 2 diabetes (Natali, Toschi et al. 2006). It has been estimated 
that more than 65% of adult diabetic patients die from cardiovascular disease or stroke 
(Grundy, Benjamin et al. 1999). Microparticles (MPs) are plasma membrane fragments 
released by stimulated cells. MPs of endothelial and leukocyte origin circulate at high levels 
in patients with cardiovascular disorders. Because they convey bioactive proteins and lipids 
and RNA to remote cells they also act as cellular effectors. (Bonello, Zahringer et al. 2007)In 
metabolic syndrome, circulating leukocyte-derived MPs were shown of prognosis value in 
sub-clinical atherothrombosis, and they accumulate into the atherosclerotic plaque. They were 
shown to favor a procoagulant and pro-inflammatory state of endothelial cells in MP-
mediated cross-talk models. (Salminen, Kaarniranta et al. 2012) 
 In diabetes, manifestations of the vascular disease are characterized by an imbalance 
of vasodilation and vasoconstriction, increased arterial stiffness, and pathological remodeling 
(Tabit, Chung et al. 2010).  High levels of pro-inflammatory cytokines and procoagulant 
endothelial-derived MPs circulate at high level in diabetic patients reflecting a pro-
inflammatory state and endothelial damage or dysfunction. (Sabatier, Darmon et al. 2002)  
Endothelial dysfunction, defined as vasoconstriction rather than arterial vasodilation 
after stimulation with endothelium-dependent agents such as acetylcholine or bradykinin is 
associated with early stages of atherosclerosis (Furchgott and Zawadzki 1980, Bonetti, 
Lerman et al. 2003) and characterized by endothelial dysfunction with reduced of 
bioavailability of vasodilators, in particular, nitric oxide (NO), whereas contracting-derived 
endothelium factors (Lerman and Burnett 1992) increase. There is strong evidence that 
hyperglycemia is deleterious to endothelial function (Taylor and Poston 1994, Dorigo, 
Fraccarollo et al. 1997, Jin and Bohlen 1997, Williams, Goldfine et al. 1998), especially with 
long-term exposure. However, a few studies have demonstrated the effects of high glucose 
with short-term exposure. (Williams, Goldfine et al. 1998, MacKenzie, Cooper et al. 2008, El-
Awady, El-Agamy et al. 2014).  
 
The presence of endothelial dysfunction is a strong risk for development of coronary 
artery disease and worsened outcome (Halcox, Schenke et al. 2002). Most studies have 
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investigated endothelial dysfunction and its determinants in peripheral arteries and only a few 
studies directly measured local changes in vascular reactivity, particularly with regard to 
coronary vasculature (Ong, Athanasiadis et al. 2014).  
Endothelial senescence is a main contributor to vascular ageing (Erusalimsky 2009, 
Wang and Bennett 2012) and is accelerated by hyperglycemia-induced generation of reactive 
oxygen species (ROS)(Doles, Storer et al. 2012). The superoxide radical generated by 
NADPH oxidase system is both a main source of ROS and a main contributor to the 
development of diabetes-associated endothelial dysfunction (Ding, Aljofan et al. 2007, 
Giacco and Brownlee 2010, Doles, Storer et al. 2012). Thus, hyperglycemia-induced ROS 
formation and decreased bioavailability of NO help promote the shortening of telomere 
length, increase genomic instability and growth arrest, increase DNA damage, which leads to 
premature senescence in endothelial cells (Hoffmann, Haendeler et al. 2001, Hayashi, Matsui-
Hirai et al. 2006, Yokoi, Fukuo et al. 2006, Ota, Eto et al. 2008, Zhong, Zou et al. 2010, 
Matsui-Hirai, Hayashi et al. 2011). In an amplification loop, endothelial senescence leads to 
the release of pro-senescent MPs and pro-senescent endothelial MPs circulate in the plasma of 
patients at cardiovascular risk. (Abbas, Jesel et al. 2017) 
In diabetes mellitus, changes in barrier function and adhesion of leukocytes and other 
circulating cells at the surface of the inflamed endothelium of the artery would favor 
endothelial dysfunction and apoptosis and the secondary release of endothelial procoagulant 
MPs. In addition, hyperglycemia prompts the apoptosis of the endothelial cells from the 
pancreatic islet vessel (Lorenzi and Cagliero 1991, Baumgartner-Parzer, Wagner et al. 1995, 
Cines, Pollak et al. 1998, Ho, Liu et al. 2000, Ido, Carling et al. 2002, Favaro, Miceli et al. 
2008). 
 
 In the present work, we studied the pro-senescent effects of MPs freshly isolated from 
the spleen and of high glucose concentration on endothelial senescence and dysfunction. MPs 
were isolated from freshly isolated splenocytes stimulated by LPS or a combination of 
phorbol myristate acetate and ionophore to mimic pro-inflammatory conditions, and 
incubated with primary coronary artery endothelial cells and with coronary artery rings to 
assess endothelial dysfunction.  
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Materials & Methods 
Animals 
Animals Male Wistar rats (Janvier-labs, Le Genest-St Isle, France) were stored in a 
temperature control room (22°C) and maintained on a standard 12-h light/dark cycle (lights 
on at 07:00 am) with free access to food and water. The experiments are consistent with the 
Guide to Care and the Use of Laboratory Animals published by the US National Institutes of 
Health (NIH publication No. 85-23, revised 1996) and were authorized by the French 
Ministry of Higher Education and Research and by the local ethic committee (Comité 
d’éthique en Matière d’expérimentation animale de Strasbourg, authorization 03799.01). All 
animal experiments were carried out in a registered animal yard within the Faculty of 
Pharmacy (Authorization number E-67-218-26). 
 
Splenocyte isolation and culture 
Spleens were withdrawn, weighed and placed in a 10-cm petri dish containing 10 ml sterile 
phosphate-buffered saline (PBS). All further steps were realized under sterile conditions. The 
spleen tissue was homogenized using a 2-ml rubber syringe plunger and the homogenate 
filtered through 100-µm sterile cell strainers into a 50-ml tube to remove cell debris. 
Following centrifugation at 300 g for 5 min, the supernatant was removed, and the cell pellet 
gently tapped for re-suspension in a 5-ml ammonium-chloride potassium (ACK) erythrocyte 
lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM Na2EDTA, pH 7.4) for 5 min. After 
centrifugation of remaining cells (300g, 5 min) and washing in PBS, the final cell suspension 
was re-suspended in RPMI-1640 medium (Sigma, St. Louis, MO) supplemented with 2 mM 
L-glutamate, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-
inactivated (56°C, 30 min) fetal bovine serum (FBS) (Gibco, Saint Aubin, France). Cells 
seeded into T75 culture flask at 3.106 cells/mL were maintained in complete RPMI-1640 
medium at 37°C in a 5% CO2 humid atmosphere until MP harvest. 
 
Generation, isolation, quantification and characterization of MPs from 
splenocytes suspension 
Splenocytes were stimulated by 5 µg/ml of lipopolysaccharide (LPS) (from Escherichia coli 
0127:B8; Sigma) or a combination of PMA (25 ng/ml; Enzo) and A12387 calcium ionophore 
(1 µM; Sigma) at 37°C in a humid atmosphere of 5% CO2 for 24 h. After 24h, recovered 
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splenocytes were numbered for each condition. MP concentration was measured by 
prothrombinase assay in the supernatant of splenocytes in response to LPS (SMPLPS) and 
PMA/I (SMPPMA/I) as compared to MPs assessed in the supernatant of untreated splenocytes 
(SMPCTL). MPs were isolated and washed by differential centrifugation of the suspension. 
Briefly, splenocytes and cellular debris were discarded by a first centrifugation step at 800 g 
for 15 min at room temperature and the supernatant submitted to a second double 
centrifugation step at 14 000 g and 4°C for 60 min. The suspension of washed concentrated 
splenocyte-derived MPs (SMP) was re-suspended in Hanks Balanced Salt Solution (HBSS) 
and was kept until use for less than one month at 4°C. MP measurement was performed by 
prothrombinase assay after capture onto Annexin-A5 coated micro-wells using a microplate 
spectrophotometer set in kinetic mode. In this assay, phosphatidylserine is the rate-limiting 
factor of the generation of thrombin from prothrombin detected at 405 nm using a 
chromogenic substrate (PNAPEP0216, cryopep, Montpellier, France). MPs concentration was 
referred to as phosphatidylserine equivalent (nM PhtdSer eq.), by reference to a standard 
curve made with synthetic vesicles of known amounts of PhtdSer (Jy, Horstman et al. 2004). 
 
Isolation and Culture of Coronary Artery Endothelial Cells (ECs) 
Pig hearts were collected from the local slaughterhouse (COPVIAL, Holtzheim, France) and 
(ECs) were isolated from the left circumflex coronary arteries as described previously 
(Khemais-Benkhiat, Idris-Khodja et al. 2016). Briefly, left circumflex coronary arteries were 
excised from the fresh heart, cleaned of adhesive conjunctive tissues, and the remaining blood 
was flushed with cold phosphate-buffered saline (PBS) without calcium. Subsequently, ECs 
were isolated by filling the artery with a type I collagenase (Worthington Biochemicals Corp., 
Lakewood, NJ) solution at 1 mg/mL dissolved in MCDB131medium (Life Technologies 
SAS, St Aubin, France) supplemented with penicillin (100 U/mL), streptomycin (100 U/mL), 
fungizone (250 mg/mL), and L-glutamine (2 mM) (all from Lonza, St Quentin en Yvelines, 
France) for 15 minutes at 37°C. ECs were collected in the effluent after circular massage of 
the arteries and the remaining cells were flushed with the medium. Collected ECs were gently 
centrifuged at 400 g, the medium was removed, and pelleted cells were suspended in 
complete MCDB131 medium solution supplemented with 15% fetal bovine serum. ECs from 
three different arteries were seeded in a T25 flask and expanded at 37°C in a 5% CO2 
humidified atmosphere for 5-6, then removing the medium containing non-adherent cells and 
replaced with a new medium, grown for 48-72 hours (passage 0). 
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Endothelial cell treatments 
ECs at passage 1 (P1 ECs) were seeded at 75%-80% confluence in multi-well plates and were 
pre-incubated with high or low glucose concentration (HG 25 mM, NG 5.5 mM) for 48h prior 
to addition SMPCTL, SMPLPS, or SMPPMA/I (10 nM) for an additional period of 48h. In all 
cases, the medium was changed every 24 h. 
 
Fluorescence detection of senescence-associated β-galactosidase (SA-β-gal) activity 
To measure Senescence-associated β-galactosidase activity (SA-β-gal) in ECs by flow 
cytometry (FACScan, Becton Dickinson, San Jose, CA, USA), we used the ﬂuorogenic 
substrate C12FDG (5 dodecanoylaminofluorescein Di-β-D-galactopyranoside, Invitrogen, Life 
Technologies SAS) as previously described (Debacq-Chainiaux, Erusalimsky et al. 2009). 
This compound is membrane-permeable and nonfluorescent, however, it emits green 
fluorescence upon excitation and remains confined within the cell after hydrolysis of the 
galactosyl residues by β-galactosidase. Briefly, ECs were pre-treated with chloroquine (300 
µM) for 1 h to raise the pH of the internal lysosomes to approximately 6. C12FDG (33 µM) 
was then added for 1 h. At the end of the incubation period, ECs were washed with ice-cold 
PBS, the following trypsinization and analyzed immediately using a ﬂow cytometer 
(FACScan, BD Biosciences, San Jose, CA). Data were acquired and analyzed using the 
CellQuest software (Becton Dickinson). Light scatter parameters were set to eliminate dead 
cells and subcellular debris. The green C12-fluorescein signal was measured, and SA-β-gal 
activity was estimated using the median fluorescence intensity (MFI) of the population. 
Autoﬂuorescence was assessed in unlabeled cells to C12FDG, was negligible. 
 
Western blot analysis 
After treatment, cells were washed twice with PBS and then lysed in extraction buffer (20 
mM Tris/HCl [pH 7.5], 150 mM NaCl, 1 mM Na3VO4, 10 mM sodium pyrophosphate, 20 
mM NaF, 0.01 mM okadaic acid, 1% Triton X-100 (Euromedex, Souffelweyershem, France), 
a tablet of complete protease inhibitor (Roche). Total proteins (20 µg or 30 µg) were separated 
on 8% or 12% sodium dodecyl sulfate-polyacrylamide gels at 100V for 2h and transferred 
electrophoretically in polyvinylidene difluoride membranes (GE healthcare, Vélizy 
Villacoublay, France) at 100V for 2 h. Membranes were incubated with blocking buffer (Tris-
buffered saline solution (TBS) and 0.1% Tween 20 [Euromedex]) containing 3% bovine 
serum albumin for 1 h. For detection of proteins, membranes were incubated overnight at 4°C 
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with blocking buffer containing the respective primary antibody: rabbit polyclonal anti-eNOS 
(diluted 1:1.000; BD Biosciences, Le Pont de Claix, France), mouse monoclonal anti-p21 
(diluted 1:500; Santa Cruz Biotechnology), mouse monoclonal anti-p16 (diluted 1:500; Santa 
Cruz Biotechnology), mouse monoclonal COX-2 (diluted 1:500 dilution; BD Biosciences), 
mouse monoclonal anti-ICAM1 (1:1000 dilution, Abcam, UK), rabbit monoclonal anti-
VCAM1 (1:1000 dilution, Abcam, UK), Anti β-actin (1:20000 dilution). After washing, 
membranes were incubated with the secondary antibody (peroxidase-labeled antirabbit and 
anti-mouse immunoglobulin G, dilution of 1:5000; Cell Signaling Technology) at room 
temperature for 1 h. Pre-stained markers (Invitrogen, France) were used for molecular mass 
determination. Immunoreactive bands were detected by enhanced chemiluminescence and 
their density analyzed using the ImageQuant acquisition system and analysis software 
(LAS4000 and ImageQuant TL 8.1, Amersham, UK). The amount of protein in each lane was 
normalized to the housekeeping protein β-actin before the analysis was performed. 
 
Immunofluorescence staining of coronary artery rings 
To characterize the mechanism underlying the HG and/or SMP-induced endothelial 
dysfunction, the expression level of several proteins involved in redox-sensitive and 
inflammatory pathways were determined by immunofluorescence in sections of the coronary 
artery. For this purpose, porcine coronary arteries (4–5 mm length) were embedded in Tissue 
Tek OCT (Sakura 4583, Leiden, The Netherlands) and frozen in a nitrogen bath for cryostat 
sections at 14 µm. Sections were air dried for 15 min and stored at −80 °C until use. Sections 
were first fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, 
USA), washed and treated with 10% milk in phosphate buffered saline containing 0.1% 
Triton X-100 for 1h at room temperature to block non-specific binding. Coronary artery 
sections were then incubated overnight at 4 °C with an antibody directed against either eNOS 
(1/1000, cat: 610297, BD Transduction Laboratories, Le Pont de Claix, France), VCAM1 
(1:1000 dilution, 134047, Abcam, UK) and COX-2 (1/250 dilution, 15191, Abcam, UK). 
Negative controls were treated with suspensions deleted of primary antibodies. Sections were 
then washed with phosphate-buffered saline, three washes were followed by incubation with 
the fluorescent secondary antibody (1/400, Alexa 633-conjugated goat antirabbit or anti-
mouse IgG, A-21070 and A-21050, Thermo Fisher, Illkirch, France) for 2 h at room 
temperature in the dark before being washed with phosphate-buffered saline and mounted in 
Dako fluorescence mounting medium (Dako S3023, Les Ulis, France) and cover-slipped 
before being evaluated by confocal microscopy using a confocal laser-scanning microscope 
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(Leica TSC SPE, Mannheim, Germany). Quantification of fluorescence levels in ECs was 
performed using Image J software (version 1.49p for Windows, US National Institutes of 
Health) after delineating the endothelial monolayer. For each condition, cumulative data were 
calculated as the mean of measurements on 6 sections and represent n=7 experimental data 
sets performed on separate occasions. 
 
 
Determination of vascular oxidative stress 
Porcine coronary artery was cleaned of connective tissue and flushed with PBS without 
calcium to remove remaining blood, cut into rings (4–5 mm in length), pre-incubated for 12 h 
under sterile conditions with HG or LG prior to addition of different concentrations of SMPs 
for 12h. After were embedded in OCT compound (Sakura Finetek, Villeneuve d’Ascq, 
France) and frozen in a nitrogen bath for cryostat sections. The redox-sensitive fluorescent 
dye dihydroethidium (DHE, 2.5 µM) was applied onto 25 µm unfixed cryosections of 
coronary arteries for 30 min at 37°C in a light protected humidified chamber. Section were 
then washed three times, mounted in (Dako, Les Ulis, France) and cover-slipped. The level of 
fluorescence in each section was examined under a confocal laser-scanning microscope (Leica 
SP2 UV DM IRBE; leica, Heidelberg, Germany) with a 20X magnification lens. 
Quantification of fluorescence levels was performed using the ImageJ software. For each 
condition, cumulative data were calculated as the mean of measurements on 6 sections and 
represent n=7 experimental data sets performed on separate occasions. 
 
 
Vascular reactivity 
Vascular reactivity studies were done in isolated porcine coronary arteries and vascular 
reactivity was assessed as indicated previously (Anselm, Chataigneau et al. 2007, Auger, Kim 
et al. 2010). Briefly, the coronary artery was cleaned of connective tissue and flushed with 
PBS without calcium to remove remaining blood, cut into rings (2–3 mm in length), pre-
incubated 12 h under sterile conditions with HG or NG in RPMI-1640 medium (Sigma, St. 
Louis, MO) prior addition of different concentrations of SMPs for 12h and then suspended in 
organ baths containing oxygenated (95% O2, 5% CO2) Krebs bicarbonate solution 
(composition in mM: NaCl 119, KCl 4.7, KH2PO4 1.18, MgSO4 1.18, CaCl2 1.25, NaHCO3 
25, and D-glucose 11, pH 7.4, at 37 ° C) for the determination of changes in isometric tension 
(basal tension 5 g). The integrity of the endothelium was checked with bradykinin (0.3 mM). 
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After equilibration and functional tests, rings were precontracted with U46619 (1–60 nM), a 
thromboxane A2 receptor agonist, before construction of concentration-response curves to 
bradykinin. Relaxations are expressed as a percentage of the contraction to U46619. For each 
condition, cumulative data were calculated as the mean of measurements performed at least 
on seven separate experiments. 
 
 
 
Statistical Analysis 
The data are expressed as mean ± standard error mean (S.E.M.) and analyzed using GraphPad 
Prism5® (Prism5 Graphpad Company, La Jolla, CA, USA). Statistical analysis between two 
groups was carried out using one-way ANOVA test followed by the Tukey’s multiple 
comparisons test. A P value <0.05 was considered significant. Experiments were conducted in 
at least in three separate experiments. 
 
 
Results 
 
SMPLPS or SMPMPA/I are specific inducers of premature senescence in young ECs and 
high glucose potentiates the pro-senescent effect of SMPLPS or SMPPMA/I. 
SMPLPS or SMPPMA/I but not SMPCTL applied at similar concentration (10 nM) significantly 
enhanced SA-ß -GAL activity by about 2-fold in NG, indicating a specific pro-senescent 
effect of SMPs released from stimulated splenocytes (SMPLPS or SMPPMA/I vs. SMPCTL, 
p<0.010, p<0.0016, respectively). As reported in a previous work from our team, exposure of 
untreated ECs to HG favored a two-fold increase in SA-ß -GAL activity compared to NG, and 
SMPCTL had no effect. However, the combination of HG and SMPLPS or SMPPMA/I led to 
additional SA-ß -GAL activity with respectively 50 % elevation and 2-fold enhancement 
compared to HG treated ECs (p<0.0117, HG vs. NG). In addition, after incubation with 
SMPLPS or SMPPMA/I in NG, a significant 2-fold enhancement in the expression of senescence 
protein markers p16, p21 was measured by western blot, and the expression of both proteins 
increased by about 4-fold in HG (p<0.0200, HG vs. NG; p<0.0012, SMPLPS or SMPPMA/I vs. 
SMPCTL, figure 2). Of note, addition to ECs of the conditioned medium of splenocytes 
deleted from SMPs by high-speed centrifugation had no effect on SA-ß -GAL activity and did 
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not modify the protein expression of relevant markers of senescence thereby excluding an 
effect of a truly soluble moiety.  
 
High glucose potentiates the SMPLPS or SMPMPA/I induced down-regulation of eNOS and 
favors ROS formation in coronary artery.  
SMPLPS or SMPPMA/I prompted a significant 2-fold and 4-fold down-regulation of eNOS in 
ECs grown respectively in NG (p<0.0014 vs. untreated ECs or SMPCTL, n=4) or HG medium 
(p<0.0001 vs. untreated ECs or SMPCTL, n=4). This observation was confirmed in porcine 
coronary rings pre-incubated with HG or NG for 12 h prior addition of SMPs for additional 
12h incubation. SMPLPS or SMPPMA/I reduced the eNOS expression measured in the 
endothelial monolayer of the rings by 60 % in NG (vs. untreated rings, p<0.0014, p<0.0001   
respectively, n=7) and by 80 % in HG (p<0.0001 vs. untreated rings, n=7), suggesting a 
blunted formation of NO. Ethidium fluorescence probing of ROS in porcine coronary artery 
showed that both SMPLPS and SMPPMA/I significantly increased ROS formation by 40 % in 
NG, which was doubled in HG medium. (figures 2 and 3) 
 
SMPLPS or SMPMPA/I are endothelial pro-inflammatory effectors ECs in response to HG 
Western blots of ECs lysates indicated that SMPLPS or SMPPMA/I induced a significant ~2-fold 
up-regulation of the endothelial expression of COX-2, ICAM-1 and VCAM-1 in NG 
(p<0.0001, SMPLPS or SMPPMA/I vs. SMPCTL, n=4) amounting to about 4 fold for SMPPMA/I in 
HG (p<0.0001 SMPPMA/I HG vs. SMPCTL NG, n=4, figure 4A). The specific pro-inflammatory 
effect of SMPLPS or SMPPMA/I was confirmed by immunostaining of the endothelial 
monolayer of the coronary rings (figure 4B) with a significant ~2-fold up-regulation of COX-
2, and VCAM-1 in NG induced by SMPLPS or SMPPMA/I (p<0.0086, SMPLPS or SMPPMA/I vs. 
SMPCTL, n=7), amounting a 4-fold increase in rings treated with SMPPMA/I in HG (p<0.0001, 
SMPPMA/I vs. SMPCTL). 
 
SMPLPS or SMPPMA/I inhibit bradykinin induced-endothelial relaxation in a 
concentration-dependent manner 
Either SMPLPS or SMPPMA/I induced a concentration-dependent inhibition of BK-induced 
relaxation, SMPPMA/I being more efficient with a 50% inhibition measured in response to 10 
nM concentration vs. 30 nM for SMPLPS in NG (p<0.0001). Of note, SMPCTL had no effect, 
even at 30 nM (figure 5A). However, the noxious effect of SMPPMA/I and SMPLPS was more 
pronounced in HG (SMPPMA/I: 85% inhibition vs. SMPCTL and SMPLPS: 80 % vs. SMPCTL, 
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p<0.0001, figure 5B).  The MP-driven inhibition of relaxation was also confirmed by the fact 
that truly soluble 5 µg/ml of LPS or 25 ng/ml /1 µM of PMA/I remained unable to alter 
vascular reactivity in response to bradykinin. In addition, MP lysates had no effect, indicating 
the pivotal role of the MP membrane structure in the endothelial targeting. It has to be noted 
that HG alone did not modify the bradykinin-induced relaxation. 
 
 
Discussion 
Previous works from our laboratory had shown that replicative or premature 
endothelial senescence occurs via redox-sensitive pathways (Khemais-Benkhiat, Idris-Khodja 
et al. 2016) and can be triggered after 4-days incubation in 25 mM Glucose supplemented 
medium. Because leukocyte-derived MPs have been described as pro-inflammatory effectors 
favoring the expression of ICAM-1 and VCAM-1 at the endothelial surface, (Salminen, 
Kaarniranta et al. 2012), eventually contributing to a prothrombotic phenotype of ECs, we 
examined the endothelial impact of MPs isolated from primary splenocytes in a model of high 
glucose-induced endothelial senescence using primary coronary ECs. We further assessed the 
impact the endothelial dysfunction induced by microparticles and high-glucose on the 
vascular tone of porcine coronary arteries using bradykinin-induced vasorelaxation.  
Taken together our data demonstrate that MPs generated from unstimulated 
splenocytes have little, if any, effect on the ECs and that MPs isolated from splenocyte 
stimulated either by PMA-ionophore or by LPS, act as specific pro-senescent and pro-
inflammatory endothelial effectors.  
In the present work endothelial-dependent bradykinin induced relaxation was impaired 
after 24h long-term exposure to HG only in the presence of SMPLPS and SMPPMA/I suggesting 
that high glucose was potentiating the effect of SMPs, possibly through glucose-induced 
exaggerated senescence favouring enhanced endothelial dysfunction and the expression of 
pro-inflammatory VCAM-1 and ICAM-1 that are ligands for leukocyte recruitment. Indeed 
while only SMPLPS and SMPPMA/I were able to prompt enhanced senescence and oxidative 
stress in ECs and coronary rings at high glucose concentration, all SMPs did prompt the 
significant up-regulation of pro-inflammatory COX-2, ICAM-1 and VCAM-1, although 
SMPCTL were less efficient. This observation suggests that the inflamed endothelium plays a 
key role at the early stage of SMP-induced endothelial senescence and dysfunction even at 
low degree of leukocyte stimulation.  
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Because Bradykinin increases endothelial nitric oxide (NO) production by activating 
endothelial NO synthase (eNOS) (Bae, Kim et al. 2003), we assessed of eNOS protein 
expression in porcine coronary artery by confocal fluorescence microscopy, and we found that 
both SMPLPS and SMPPMA/I induced a significant 2-fold decrease in eNOS expression in NG 
that was magnified to a 4-fold drop in HG.  
Our data demonstrate that high glucose reduces bradykinin-induced endothelial-
dependent relaxation of the coronary artery, favors coronary endothelial senescence and the 
accumulation of ROS and a pro-inflammatory endothelial development of arteriosclerotic 
plaques. They are in accordance with previous data indicating that high glucose (20 mM) 
impair bradykinin -induced relaxation of human subcutaneous arteries within 2 hours whereas 
opposite results were obtained in human mesenteric arteries (MacKenzie, Cooper et al. 2008). 
Of note, exposure of aortic rat rings to high glucose (44 mM) for 3h led to the attenuation of 
phenylephrine-induced contraction (El-Awady, El-Agamy et al. 2014), suggesting that HG 
may alter the vascular competence by altering both contraction and relaxation-dependent 
pathways.  
Altogether our data demonstrate that the glucotoxicity exerts noxious effects on 
coronary artery endothelial cell function by acting as a potentiator of the pro-senescent effects 
of leukocyte MPs, provided they were generated in response to a pro-inflammatory stimulus. 
They also indicate that exposure to high glucose concentration also triggers endothelial 
inflammation and ROS formation, a process known to favor leukocyte recruitment at 
coronary sites prone to athero-thrombosis. In addition, our model could prove useful to 
investigate new endothelial pharmacological targets and protect the endothelium from 
prosenescent mediators eventually conveyed by leukocyte MPs.  
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Figure legends 
 
Figure 1:  SMPLPS or SMPPMA/I but not SMPCTL induce SA-β GAL activity in young ECs 
and high glucose potentiates the pro-senescent effect of SMPLPS or SMPPMA/I. ECs were 
pretreated in 25 mM (HG) or 5.5 mM normal glucose (NG) culture medium during 48h before 
an additional 48h treatment with SMPs. SA-β GAL activity was further measured by flow 
cytometry using the fluorescent substrate FDG. SMPLPS: SMPs from LPS-stimulated 
splenocytes, SMPPMA/I: SMPs from PMA/I-stimulated splenocytes, SMPCTL were harvested 
from the supernatant of unstimulated splenocytes. FDG-: unlabeled ECs 
 
Figure 2:  SMPLPS or SMPPMA/I but not SMPCTL induce the up-regulation of senescence 
markers p21, P16 and down-regulate the expression of eNOS. High Glucose potentiates 
the SMPLPS or SMPPMA/I effects. ECs were pre-treated in 25 mM (HG) or 5.5 mM normal 
glucose (NG) culture medium during 48h before an additional 48h treatment with SMPs (A). 
Expression of p21 and down-stream p16 senescent makers was assessed by western blot as a 
ratio of the expression of ß actin. Upper panel:  representative blot, lower panel: cumulative 
data of 4 separate experiments. Porcine coronary rings were pre-incubated in HG or NG 
culture medium for 12 h prior addition of SMPs for additional 12h incubation (B). eNOS 
expression by the endothelial monolayer was measured by immunofluorescence staining of 
ring sections. Upper panel cumulative data of 7 separate experiments performed likewise. 
SMPLPS: SMPs from LPS-stimulated splenocytes, SMPPMA/I: SMPs from PMA/I-stimulated 
splenocytes, SMPCTL were harvested from the supernatant of unstimulated splenocytes.  
  
Figure 3:  SMPLPS or SMPPMA/I but not SMPCTL induce ROS formation in coronary 
artery rings and high glucose exaggerates the pro-oxidant effect of SMPs. Porcine 
coronary rings were pre-incubated in HG (25 mM glucose) or NG (5.5 mM glucose) culture 
medium for 12 h prior addition of SMPs for additional 12h incubation. ROS formation was 
assessed through ethidium fluorescence by microscopy. Data are expressed as fold increase in 
fluorescence. Lower panel example of section staining, Upper panel cumulative data of 7 
experiments performed likewise. SMPLPS: SMPs from LPS-stimulated splenocytes, 
SMPPMA/I: SMPs from PMA/I-stimulated splenocytes, SMPCTL were isolated from the 
supernatant of unstimulated splenocytes.  
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Figure 4: High glucose is a potent enhancer of the endothelial up-regulation of 
inflammatory markers COX-2, VCAM-1, ICAM-1 by SMPLPS or SMPPMA/I and is less 
efficient in the presence of SMPCTL. The expression of inducible COX-2, of ICAM-1 and 
VCAM-1 was assessed by western blot in ECs grown in 25 mM high glucose (HG) or 5.5 
mM normal glucose (NG) medium (4-A) and by immunofluorescence microscopy in the 
endothelial monolayer of coronary artery rings (4-B).  ECs were pre-treated in NG or HG 
culture medium during 48h before an additional 48h treatment with SMPs. Expression pro-
inflammatory protein makers was assessed by western blot as a ratio of the expression of ß 
actin. Porcine coronary rings were pretreated 12 hours in HG or NG medium and further 
incubated with SMPs for 12h. SMPLPS: SMPs from LPS-stimulated splenocytes, SMPPMA/I: 
SMPs from PMA/I-stimulated splenocytes, SMPCTL were harvested from the supernatant of 
unstimulated splenocytes.  
 
Figure 5: SMPLPS or SMPPMA/I and not SMPCTL impair aortic ring relaxation induced by 
bradikynin and HG enhances the noxious effect. Rings (2–3 mm in length), were pre-
incubated 12 h under sterile conditions with HG or NG in RPMI-1640 medium (Sigma, St. 
Louis, MO) prior addition of different concentrations of SMPs for 12h and then suspended in 
organ baths containing oxygenated buffer for analysis of the bradykinin-induced relaxation. In 
a first set of experiments rings were incubated with SMPLPS (5 nM-30nM) SMPLPS (2 nM-
10nM) in 5.5 mM normal glucose (NG) culture medium (figure 5A). In a second set of 
experiments SMPPMA/I, SMPLPS were incubated at 10 nM in high glucose culture medium (25 
mM). SMPCTL were incubated at 10nM or 30 nM concentration as indicated on the graph 
(figure 5B)  
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Figure 2B 
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Figure 4 B 
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1- Background  
 
The endothelial dysfunction observed in the macro and microsvaisseaux of patients with DT2 
diabetes patients are the consequence of specific mechanisms pertaining to diabetes namely 
hyperglycemia but also to other CV risk factors.  
In the Multiple Risk Factor Intervention Trial (MRFIT, 347,978 people) the absolute risk of 
CVD death was about 3-fold higher in diabetics than in non-diabetics, and this risk increased 
with the combination of CV risk factors (Stamler, Vaccaro et al. 1993). Therefore, the 
therapeutic management of diabetes should take into account the glycemic balance but also 
CV risk factors associated with diabetes and possibly the contribution of endothelial 
dysfunction and senescence. In the ADVANCE interventional study, a reduction of systolic 
blood pressure of 5.6 mmHg in diabetic patients receiving a combination of perindopril and 
indapamide resulted in a 9% reduction in macro and microvascular major, compared to those 
who received a placebo (Patel, Chalmers et al. 2005).   
Glucose homeostasis is largely mediated by glucose uptake from dietary carbohydrates in the 
small intestine and by filtration and reabsorption into the kidney. Recently, gliflozins a new 
class of antidiabetes drugs that inhibit renal glucose re-uptake by SGLT1 and SGLT2 
receptors, were shown to favour glucosuria and lower blood glucose independently of 
glycemia. A striking outcome of the different clinical trials was the early and major decrease 
of cardiovascular morbidity and mortality that was significant within the first 3 months after 
initiation of the treatment (EMAPREG,CANVAS,DECLARE).   
 Since the lipid bilayer of cell membranes is impermeable to this hydrophilic molecule, 
specialized transport proteins are required for its passage from the extracellular medium to the 
intracellular medium. Two types of glucose transporters, GLUTs and SGLTs are known, at 
least 14 GLUTs and 12 SGLTs have been identified (Wright, Loo et al. 2011).  
 
 
1-1 Glucose transport by SGLT1 and SGLT2 
SGLTs transport glucose across cell membranes against its concentration gradient. It is an 
active, so-called secondary transport that uses the energy created by a sodium gradient. It 
should be noted that the sodium gradient is maintained by the Na + / K + ATPase pump and 
stabilizes the membrane potential.  
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Figure 14:  Glucose transport via SGLTs in renal tubule (Beaud, Pruijm et al. 2015) 
Wright's and colleagues, described in the early 1980s, the existence of a co-transporter of 
Sodium-coupled glucose can be inhibited by phlorizine, a natural substance used as a 
research tool to induce kidney glycosuria.  
 
 
1-1.1 SGLT1 is mainly expressed in the apical membrane of epithelial cells of the brush 
border of the small intestine, and in the S3 segment of the renal proximal tubule, where it is 
responsible for the reabsorption of approximately 10% of the filtered glucose. hSGLT1 
mRNA has been detected in the heart, testes, prostate, colon, trachea, lung, brain, spinal cord, 
spleen, liver, the uterus, pancreas and blood vessels (Poppe, Karbach et al. 1997, Zhou, Cryan 
et al. 2003, Chen, Williams et al. 2010). In humans, mutations in the SGLT1 gene are 
responsible for a rare autosomal recessive disorder: intestinal glucose-galactose malabsorption 
(GGM) (Turk, Kerner et al. 1996, Martin, Wang et al. 2000) causing severe osmotic diarrhea 
by excess of unabsorbed glucose and galactose in the intestinal lumen,  
1-1.2 SGLT2 is expressed by the apical membrane of the brush border epithelial cells of the 
S1 and S2 segments of the proximal renal tubule, it transports sodium-coupled glucose with 1 
Na + stoichiometry. / 1 glucose (Kanai, Lee et al. 1994) and is responsible for the 
reabsorption of 90% of the glucose filtered at the renal level. hSGLT2 mRNA was detected in 
the testes, cerebral arteries and cerebellum and pancreas (Zhou, Cryan et al. 2003, Chen, 
Williams et al. 2010, Wright, Loo et al. 2011, Bonner, Kerr-Conte et al. 2015). SGLT2 
transports glucose from the glomerular filtrate into epithelial cells of the tubule and GLUT2 
facilitates the release of glucose through the basolateral membrane to the interstitial fluid from 
which it will be captured by the peritubular capillaries to reach the bloodstream (Abdul-
Ghani, Norton et al. 2011). Mutations in the SGLT2 sequence are responsible for familial 
renal glycosuria (FRG) (Calado, Sznajer et al. 2008, Santer and Calado 2010). This benign 
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genetic defect causes persistent glycosuria, with glucose excretion up to 160 g / day, without 
hypoglycaemia. 
 
1-2- SGLT1 and SGLT2 expression in diabetes and cardiovascular disorders 
In cardiac ischemia and heart failure the glucose requirements of cardiomyocytes are 
increased (Tian, Gong et al. 2001). In a diabetes context, the glucose transport is enhanced in 
skeletal muscle cells, renal epithelial cells, hepatocytes and adipocytes hence to GLUTs and 
SGLT1 and SGLT2 overexpression (Banerjee, McGaffin et al. 2009, Balteau, Tajeddine et al. 
2011, Bogan, Rubin et al. 2012).  
In human cardiac tissue, the expression of SGLT1 is increased in subjects with diabetes and 
ischemic cardiomyopathy, possibly as a result an adaptive change in response to a reduction 
in cardiac expression of GLUT1 and GLUT4. Interestingly, the myocardial expression of 
SGLT1 seems to increase with age with a level of SGLT1 mRNA gradually increased 
between 2 and 20 weeks in mice (Banerjee, McGaffin et al. 2009).  
Glucose is the main modulator of SGLT1 gene expression in the gut and kidney (Lescale-
Matys, Dyer et al. 1993, Vayro, Wood et al. 2001), but in brain ECs, SGLT1 would maintain 
adequate glucose concentration under only hypoglycemia conditions. 
 
Interestingly, SGLT2 transporters are overexpressed by proximal tubule epithelial cells in 
diabetic patients (Rahmoune, Thompson et al. 2005), presumably following an adaptive 
response to the increase in glomerular glucose filtration., the overexpression of SGLT2 
increasing the capacity for renal glucose reabsorption. Inhibitors of SGLT2 therefore decrease 
the maximal capacity of glucose reabsorption by the renal proximal tubule, in the context of 
diabetes. As for the expression of SGLT1 in diabetes, the observations diverge. Studies have 
provided evidence of increased, unchanged, or reduced expression and / or activity of SGLT1 
in animal models of diabetes, or in vitro under high glucose conditions (Vallon and Thomson 
2012).  
 
 
The expression of SGLT1 and SGLT2 transporters is also enhanced after exposure of renal 
epithelial cells to HG and associated with increased secretion of pro-inflammatory cytokines 
(IL-6, TNF-α) that in turn also induce the auctocrine induction expression of SGLT2 but not 
of SGLT1, indicating an autocrine modulation of SGLT2 expression by cytokines 
(Maldonado-Cervantes et al., 2012), on line with the pro-inflammatory status of diabetes 
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patients. In diabetic patients, the plasma and urinary levels of IL-6 and TNF-α are high, and 
correlate with the progression of diabetic nephropathy (Navarro-Gonzalez and Mora-
Fernandez 2008). SGLT2 expression is also increased in epithelial cells of the renal tubule of 
hypertensive rats (Bautista, Manning et al. 2004) and in the kidney DT2 animal models and in 
diabetic subjects (Freitas, Anhe et al. 2008, Vallon 2011), suggesting its relevance as a 
pharmacological target to reduce the cardiovascular morbidity and restore normal glycemia. 
(Rahmoune, Thompson et al. 2005).  
 
1-3- SGLT1 and SGLT2 and cellular dysfunction  
At the cellular level,  SGLT1 seems involved in the activation of NADPH oxidase by "high 
glucose" in cardiomyocytes (Balteau, Tajeddine et al. 2011), whereas glucose metabolites (O-
linked N-acetylglucosamine, glucose 6-phosphate) play no role, thereby suggesting that 
SGLT1 is key in NADPH oxidase activation and ROS production in response to high glucose, 
independently of glucose metabolism. (Balteau, Tajeddine et al. 2011). 
 Hydrogen peroxide and insulin induce SGLT2 overexpression in renal epithelial cells. The 
increased glucose uptake and ROS generation induced by insulin is prevented by pre-
treatment with the NAC antioxidant, suggesting a key role of ROS in regulating SGLT2 
expression (Nakamura, Matsui et al. 2015).  
Renal tubular cells of patients with diabetic nephropathy have a senescent phenotype 
(Verzola, Gandolfo et al. 2008) that may be involved in the pathophysiology of diabetic 
nephropathy and hyperglycemia causes renal tubular epithelial cell senescence by an SGLT2-
dependent mechanism in a model of streptozotocin-induced type 1 diabetes mellitus in mice. 
In vitro, the exposure of human proximal tubular cells to high glucose concentrations also 
increases the expression of senescence markers, that was reduced in the presence of SGLT2 
siRNA, (Kitada, Nakano et al. 2014).  
 
 
 
2- Rationale 
The levels of endothelial cell-derived microparticles (EMP) are significantly increased in 
diseases with systemic endothelial damage as seen in diabetes mellitus and coronary artery 
disease (Rautou, Vion et al. 2011). We therefore anticipated that the vessel itself would 
contribute to autocrine dysfunction through the release of pro-senescent EMPs. Taken 
together, the above data from the literature, our data reported in part 1, and those from other 
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members of the laboratory (Sonia Khemais, thesis 2017), suggest that SGLT2 is key to 
hyperglycemia-induced endothelial senescence and dysfunction in the vessel. Main 
hypothetical mechanisms would include endothelial ROS accumulation, pro-inflammatory 
phenotype, enhanced cytokine secretion, recruitment of leukocytes and derived MPs, leading 
to SGLT2 overexpression.  Although SGLT1 involvement is less ascertained, we chose to 
explore the effects of a SGLT1/2 inhibitor and of a SGLT2 specific inhibitor to examine the 
role high glucose-induced endothelial senescence on the pro-senescent action of SR-MPs in 
coronary artery rings. Rings were incubated for 18h with high glucose under strict sterile 
conditions before assessment of the senescence and pro-inflammatory markers and 
endothelial-dependent vascular reactivity.  These unusual conditions were chosen as a pre-
requisite since they enable the measurement of SR-MP vascular effects.  
 
Preliminary data that show the optimization of the model and the first results are described in 
the following pages. They concern the effect of high glucose and SGLT inhibitors (SGLTi )on 
the release of MPs from the coronary ring, on the endothelial-dependent contraction and on 
the expression of pro-inflammatory and pro-senescent markers using standardized ring 
incubation procedure (18h) and the standardized MP extraction procedure from islosated 
splenocytes described in part 1. SGLTi were incubated simultaneously were also explored 
(see figure below). 
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3- Preliminary manuscript 
Materials and methods  
 
Generation, isolation, quantification and characterization of MPs from 
porcine coronary artery 
Washed porcine coronary artery fresh artery were cut using a device containing a succession 
of fixed razor blades (1mm) then incubated with (HG or NG) on a rolling device (17 rpm) in 
RPMI-1640 medium (Sigma, St. Louis, MO) at room temperature for 1h30 min. After 
centrifugation at 800 g, 20°C for 15 min to discard cell debris and a further double 
centrifugation step at 14000 g, 4°C for 5min (two times), the washed isolated MPs were re-
suspended in HBSS (Hanks Balanced Solution and their concentration was determined by 
prothombinase assay or Coomassie protein assay.  
 
Vascular reactivity 
Porcine coronary artery rings (2-3 mm were incubated for 18h at high glucose concentration 
(HG) or normal concentration (HG 25 mM, NG 11 mM) in RPMI-1640 medium (Sigma, St. 
Louis, MO). In some experiments, rings were incubated with pharmacological agents : 
LX4211 (Lexicon), a dual SGLT2/1 (10-7M), a highly selective SGLT2 inhibitor (SGLT2i, 
10-7M). After incubation, rings were washed in HBSS, and U46619-induced endothelium-
dependent contraction was assessed in organ chambers. (Anselm, Chataigneau et al. 2007, 
Auger, Kim et al. 2010). Rings were suspended in organ baths containing oxygenated (95% 
O2, 5% CO2) Krebs bicarbonate solution (composition in mM: NaCl 119, KCl 4.7, KH2PO4 
1.18, MgSO4 1.18, CaCl2 1.25, NaHCO3 25, and D-glucose 11, pH 7.4, at 37 ° C) for the 
determination of changes in isometric tension (basal tension 5 g). The integrity of the 
endothelium was checked with bradykinin (0.3 mM). After equilibration and functional tests, 
rings were contracted with U46619 (10-9 –10-6M). 
 
Western blot analysis 
After 24h incubation of the rings with HG and NG medium, rings were washed twice with 
HBSS and directly frozen in liquid nitrogen and store at -80°C.  The ring tissue was grinded 
and then lysed in extraction buffer (20 mM Tris/HCl [pH 7.5], 150 mM NaCl, 1 mM Na3VO4, 
10 mM sodium pyrophosphate, 20 mM NaF, 0.01 mM okadaic acid, 1% Triton X-100 
(Euromedex, Souffelweyershem, France), a tablet of complete protease inhibitor (Roche). 
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Total proteins (20 µg or 30 µg) were separated on 8% or 12% sodium dodecyl sulfate-
polyacrylamide gels at 100V for 2h and transferred electrophoretically in polyvinylidene 
difluoride membranes (GE healthcare, Vélizy Villacoublay, France) at 100 V for 2 h. 
Membranes were incubated with blocking buffer (Tris-buffered saline solution [TBS] and 
0.1% Tween 20 (Euromedex) containing 3% bovine serum albumin for 1 h. For detection of 
proteins, membranes were incubated overnight at 4°C with blocking buffer containing the 
respective primary antibody: rabbit polyclonal anti-eNOS (diluted 1:1.000; BD Biosciences, 
Le Pont de Claix, France), mouse monoclonal anti-p21 (diluted 1:500; Santa Cruz 
Biotechnology), mouse monoclonal anti-p16 (diluted 1:500; Santa Cruz Biotechnology), 
mouse monoclonal COX-2 (diluted 1:500 dilution; BD Biosciences), mouse monoclonal anti-
ICAM1 (1:1000 dilution, Abcam, UK), rabbit monoclonal anti-VCAM1 (1:1000 dilution, 
Abcam, UK), Anti β-actin (1:20000 dilution). After washing, membranes were incubated with 
the secondary antibody (peroxidase-labeled antirabbit and anti-mouse immunoglobulin G, 
dilution of 1:5000; Cell Signaling Technology) at room temperature for 1 h. Pre-stained 
markers (Invitrogen, France) were used for molecular mass determination. Immunoreactive 
bands were detected by enhanced chemiluminescence and their density analyzed using the 
ImageQuant acquisition system and analysis software (LAS4000 and ImageQuant TL 8.1, 
Amersham, UK). The amount of protein in each lane was normalized to the housekeeping 
protein, β-actin before the analysis was performed. 
 
Immunofluorescence studies 
Immunofluorescence labelling was performed in sections (4–5 mm length) of the coronary 
artery that were embedded in Tissue Tek OCT (Sakura 4583, Leiden, The Netherlands) and 
frozen in a nitrogen bath for cryostat sections at 14 µm. Sections were air dried for 15 min and 
stored at −80 °C until use. Sections were first fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA, USA), washed and treated with 10% milk in phosphate 
buffered saline containing 0.1% Triton X-100 for 1h at room temperature to block non-
specific binding. Coronary artery sections were then incubated overnight at 4 °C with an 
antibody directed against either eNOS (1/1000, cat: 610297, BD Transduction Laboratories, 
Le Pont de Claix, France), VCAM1 (1:1000 dilution, 134047, Abcam, UK) and COX-2 
(1/250 dilution, 15191, Abcam, UK). For negative controls, it has been deleted primary 
antibodies. Sections were then washed with phosphate-buffered saline, three washes were 
followed by incubation with the fluorescent secondary antibody (1/400, Alexa 633-conjugated 
goat antirabbit or anti-mouse IgG, A-21070 and A-21050, Thermo Fisher, Illkirch, France) for 
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2 h at room temperature in the dark before being washed with phosphate-buffered saline and 
mounted in Dako fluorescence mounting medium (Dako S3023, Les Ulis, France) and cover-
slipped before being evaluated by confocal microscopy using a confocal laser-scanning 
microscope (Leica TSC SPE, Mannheim, Germany). Quantification of fluorescence levels in 
ECs was performed using Image J software (version 1.49p for Windows, US National 
Institutes of Health) after delimitation of the endothelial monolayer. 
 
Determination of vascular oxidative stress 
Porcine coronary artery was cleaned of connective tissue and flushed with PBS without 
calcium to remove remaining blood, cut into rings (4–5 mm in length), pre-incubated for 12 h 
under sterile conditions with HG or NG prior to addition of different concentrations of SMPs 
for 12h. After were embedded in OCT compound (Sakura Finetek, Villeneuve d’Ascq, 
France) and frozen in a nitrogen bath for cryostat sections. The redox-sensitive fluorescent 
dye dihydroethidium (DHE, 2.5 µM) was applied onto 25 µm unfixed cryosections of 
coronary arteries for 30 min at 37°C in a light-protected humidified chamber. Section were 
then washed three times, mounted in (Dako, Les Ulis, France) and cover-slipped. The level of 
fluorescence in each section was examined under a confocal laser-scanning microscope (Leica 
SP2 UV DM IRBE; leica, Heidelberg, Germany) with a 20X magnification lens. 
Quantification of fluorescence levels was performed using the ImageJ software. 
 
 
 
  
 111 
 
Results 
MPs release from freshly isolated splenocytes is enhanced by high glucose and prevented 
by simultaneous incubation with SGLT2i  
We examined whether HG induced and increased microparticles (MPs) shedding from 
porcine coronary artery rings. Compared to NG, HG induced an early and significant 0.41 
fold enhancelent in microparticles (MPs) shedding measured in the medium after 50 min 
incubation, whereas incubation with the SGLTi inhibitor restored baseline level of MP 
sehedding. Symetrically, cell recovery was reduced in HG and restored in the presence of the 
10-7 M SGLTi inhibitor, thereby strongly suggesting an protective effect-mediated by SGLT2 
targetting 
 
 x  
 
  
Figure 1 : Splenocyte recovery (up) and MP shedding (down) after 50 min incubation at 
high glucose (HG) or normal glucose (NG) concentration in the presence of 10-7 M 
SGLT2i. MPs were measured by prothrombinase assay, n=6 
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Inhibition of the U46619-induced contraction by HG is endothelial-dependent 
Incubation of the coronary rings in 25 mM glucose (HG) during 18h inhibited U46619-
induced contraction by 77.28% compared to Low Glucose medium (11 mM, LG), whereas 10-
7M SGLT2i significantly limited the HG inhibitory effect down to 26.92%, suggesting a 
SGLT2-mediated effect. The endothelial-dependence of the HG-mediated effect was 
confirmed by removal of the endothelial monolayer that led to a contraction response identical 
to that observed in LG rings. Of note, removal of the monolayer of LG-incubated rings did 
not alter the contractile response. Furthermore, replacement of the SGLT2i by a dual inhibitor 
of SGLT1 and SGLT2 did not restore contraction. Taken together these data suggested that 
HG induced a paradoxical inhibition and of the coronary vaso-contraction mediated by 
endothelial SGLT2 (see figure 2).  
 
 
 
Figure 2 : HG reduces the vasocontraction of coronary artery rings in an endothelial 
dependent manner and SGLTi2 inhibitor prevents its effects. 10-7 M SGLT2nhibitor or 
dual SGLT1/2. Tram : inhibitor of SKCa and URL: inhibitor of IKCa. Both inhibitors were 
added  in the water bath to abolish EDHF. E- removed endothelial monolayer, E+ with 
monolayer. Inhibitors of LG 11 mM Glucose, HG, 25 mM glucose, n=6   
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SGLT2i prevents ROS accumulation induced by HG in response in coronary artery 
endothelial cells and prevents eNOS down regulation.  
After 24 h incubation, HG prompted a 50 % increase of the endothelial ROS in coronary 
artery sections measured by the redox-sensitive fluorescent probe dihydroethidium (DHE) 
that was reduced by SGLT2i to baseline observed in LG. In addition a 40 % down refgulation 
of eNOS was also observed, that was counteracted by SGLTi2 (figures 3 and 4) 
 
 
Figure 3 : HG favors ROS accumulation in the endothelial layer of coronary rings that 
is prevented by SGLTi inhibitor. 10-7 M SGLT2inhibitor LG: 11 mM glucose HG: 25 mM 
glucose , n=6   
 
 
 
 
Figure 4 : HG favors the down regulation of eNOS in the endothelial layer of coronary 
rings that is prevented by SGLTi inhibitor. 10-7 M SGLT2inhibitor LG: 11 mM glucose 
HG: 25 mM glucose , n=6   
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SGLT2i prevents the HG-induced up-regulation of pro-adhesion and pro-inflammatory 
proteins VCAM-1,  ICAM-1 and inducible COX-2 in coronary rings  
 
HG also induced a significant endothelial VCAM-1 (+50%), ICAM-1 (+50%), and COX-2 by 
(+200%) measured by western blots, whereas SGLT2i blunted the HG-mediated effect. 
 
 
 
Figure 5: HG favors the up-regulation of pro-inflammatory proteins in coronary rings 
that is prevented by SGLTi inhibitor. 10-7 M SGLT2inhibitor LG: 11 mM glucose HG: 25 
mM glucose, n=6, upper panels representative western blot, lower panel cumulative data of 6 
experiments performed likewise.   
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Conclusion 
In this second set of preliminary experiments, we confirmed that overnight incubation 
of coronary ring with high glucose (HG) led to a major alteration of the vascular competence 
with a specific and paradoxical loss of vaso contraction that was endothelium-dependent and 
appears SGLT2 mediated.  
Indeed, the addition of SFGLT2i that was incubated for 18h also completely abolished the 
HG-induced loss of vaso-contraction whereas Tram and UCL inhibitors of EDHF added  in 
the water bath partially counteracted the loss of contractile response to U46619.  
It is tempting to anticipate that part of the HG-mediated dysfunction of the endothelium could 
be the consequence of premature senescence as reported in endothelial ECs by S. Khemais 
(Thesis 2017). However, the data are two preliminary to draw a conclusion on the 
mechanisms mediated by SGLT2 and to determine whether they are only supported by the 
endothelium or pro-senescent derived EMPs in a autocrine amplification loop, as already 
described in a model of isolated coronary endothelial cells by M. Abbas. (Abbas, Jesel et al. 
2017). 
Further measurements of SA- Gal activity in the OCT sections or western blot analysis of 
p21, P16 senescence markers could bring some information. 
Since high levels of cytokines and inflammatory factors such as TNFα, interleukin-6, soluble 
ICAM protein have been found in the serum of diabetic patients and animals (Wu, Liang et al. 
2016), we also assessed inflammatory markers induced by HG in porcine coronary artery and 
the possibility of their inhibition by SGLT2-. Since high levels of cytokines and inflammatory 
factors such as TNFα, interleukin-6, soluble ICAM protein have been found in the serum of 
diabetic patients and animals (Wu, Liang et al. 2016), we further assessed inflammatory 
markers induced by HG in porcine coronary artery and the possibility of their inhibition with 
EMPA. 
Some limitations to the model remain to be solved before examining the effect of SR-MPs on 
coronary rings:  
- The small quantity of medium to eventually measure MP release 
- The high sensitivity to endotoxins  
- The lack of SGLT2 and SGLT1 efficient antibodies or probes for the identification 
of tissue SGLTs  
- The low level of expression of SGLT1 and SGLT2.  
 116 
VI -General discussion and conclusion 
 
It seems that one of the key factors in ageing is the oxidative stress, resulting from the 
imbalance between the excessive production of reactive oxygen species (ROS). Free radicals 
promote oxidative damage to cellular macromolecules (DNA, lipids and proteins) (Haddad 
2002, Bonello, Zahringer et al. 2007, Venkatesan, Mahimainathan et al. 2007). The ability to 
repair DNA damage is significantly reduced (50-75%; P<0.01) with age (Cabelof, Raffoul et 
al. 2002), and less responsive to oxidative stress (Edwards, Rassin et al. 1998). 
 
In addition to the redox-sensitive alterations, ‘inflammaging’, i.e. pro-inflammatory 
phenotype that accompanies aging in mammals (Salminen, Kaarniranta et al. 2012) has been 
described. Indeed, exaggerated inflammatory responses contribute to the pathogenesis of 
chronic diseases like type 2 diabetes and obesity, two conditions that contribute to aging and 
cardiovascular risk (Barzilai, Huffman et al. 2012). As a proof of concept, genetic and 
pharmacological inhibition of NF-κB signaling prevents age-related features in different 
mouse models (Osorio, Barcena et al. 2012, Tilstra, Robinson et al. 2012) 
 
The aim of our work was to better understand the relationships between high glucose-
induced vascular damage, inflammaging and endothelial dysfunction.    
 
For this purpose, we chose to use microparticles from spleen cells as the signature of 
immune-competence of the immune cells of young and aged rats to examine whether their 
interactions with the endothelium could accelerate the process of senescence under conditions 
mimicking hyperglycemia.  
 
The choice of primary cell sources enabled the identification of the pro-senescent 
action of leukocyte MPs on isolated coronary endothelial cells and also in coronary rings. 
Interestingly, high glucose was a specific enhancer of all LMP-mediated alterations of the 
endothelial phenotype and function that were characterized by enhanced expression of 
inflammatory and oxidative markers.  
 
In addition, we could demonstrate that ageing is indeed altering the tissue environment 
since we could measure a progressive MP shedding with the age of the spleen. Finally, we 
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could measure HG-mediated dysfunction that was characterized by the paradoxical loss of 
endothelial-dependent contraction, most probably mediated through SGLT2 receptors. 
 
Our data are on line with the description of enhanced inflammatory responses, and 
immune senescence favoring the decline of the immune system with age (Deeks 2011).  
 
Many in vitro studies have confirmed that MPs derived from different cell origins could 
induce endothelial dysfunction (Brodsky, Zhang et al. 2004, Mezentsev, Merks et al. 2005). In 
our work we showed that SR-MPs from stimulated splenocytes induced ROS accumulation 
and eNOS down-regulation, two causes of endothelial dysfunction. Nevertheless the exact 
molecular redox-sensitive mechanisms at the origin of the HG and SR-MP mediated 
senescence remain to be deciphered.  
 
 
 
HG potentiates the pro-senescent effects of SMPs from stimulated splenocytes in 
coronary ECs and favors endothelial dysfunction. This figure that summarizes our data. It 
indicates that conversely to MPs isolated from stimulated splenocytes (SMPPMA/I or SMPLPS), 
MPs from naïve splenocytes (SMPCTL) do not exert an effect on endothelial-dependent 
vascular responses. We observed the up-regulation of inflammation and senescence markers 
and the down regulation of e-NOS in isolated coronary endothelial cells or in the endothelial 
layer of coronary tissues and ROS accumulation. We also observed a reduction of the 
endothelial-dependent relaxation to bradykinin in response to SMPPMA/I or SMPLPS and at 
high glucose concentration. Our data also suggest that MPs target the EDCF response while 
reducing the endothelial relaxation in response to bradykinin.  
VCAM-1
NO
L-Arginine eNOS
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Because within the vessel, MPs act as procoagulant and pro-inflammatory effectors in 
amplification loops favouring the dissemination of noxious signals to endothelial cells, one 
further step of the present work would be to examine the impact of pro-senescent leukocyte  
MPs on the secondary release of procoagulant MPs by the endothelium. In addition, the 
identification of the molecular mediators of the SR-MP that initiated the accelerated 
endothelial senescence remain to be identified eventually by comparison with their 
counterparts isolated from unstimulated SR-MPs.  
 
Finally, in our model, while the spleen appears an interesting tool as a source of primary cells 
eventually modulated by the animal treatment, it has the drawback of constituting an 
heterogeneous population of immune cells. To further identify the cell origin of the noxious 
pro-senescent SR-MPs their phenotype should be characterized before selective depletion of 
distinct MP population could be envisioned to confirm specific interactions with the 
endothelium.    
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Interactions between coronary artery 
endothelial cells and leukocyte MPs shed 
in response to E. coli lipopolysaccharide: 
In-vitro and ex-vivo studies of the impact of 
vascular ageing and of high glucose 
 
Résumé 
Les microparticules (MP) sont des vésicules de la membrane plasmique émises 
après stress cellulaire. Nous avons étudié le rôle des MPs leucocytaires extraites de 
la rate de rats comme marqueur du vieillissement et effecteurs de la senescence et 
de la dysfonction endothéliales induites par les fortes concentrations de glucose 
(HG). L’émission basale de MP augmente avec l’âge qui favorise leur génération en 
réponse au LPS ou au PMA/ionophore A23187 (MPLPS, MPPMA/I).  Les MP de rats 
âgés mais pas de jeunes induisent la sénescence de cellules endothéliales primaires 
d’artères coronaires (AC) de porc. MPLPS ou MPPMA/I de rats jeunes, mais pas MPCTL 
(cellules non traitées) réduisent la relaxation dépendante de l’endothélium d’anneaux 
d’AC en réponse à la bradykinine avec sous-expression de eNOS, surexpression de 
COX2, ICAM-1, VCAM-1. HG favorise l’émission des MP de rate. Dans les AC en 
HG, la vasoconstriction en réponse au U46619l est diminuée de manière dépendante 
du SGLT1/2 et de l’EDHF.  
Microvesicules tissulaires, microparticules tissulaires, sénescence et dysfonction 
endothéliale.  
 
Résumé en anglais 
Microparticles (MP) are plasma membrane vesicles shed from stimulated cells. We 
investigated whether leukocyte MP extracted from rat spleen are reliable markers of 
aging and effectors of high glucose (HG)-induced endothelial senescence and 
dysfunction. Data indicate that ageing enhances MP shedding from spleen cells of 
middle-age and aged rats and raises MP release in response to LPS, or to PMA and 
ionophore A23187. Of note, MP from aged but not young rats induced senescence of 
porcine coronary artery primary endothelial cells. In young rats, MPLPS, MPPMA/I but 
not from resting cells (MPCTL) reduced the endothelial-dependent relaxation of 
coronary artery rings (CAR) in response to bradykinin with down-regulation of eNOS, 
up-regulation of COX-2, ICAM-1, VCAM-1. HG enhanced early and late MP release 
from spleen cells. Prolonged exposure to HG potentiated endothelial dysfunction in 
CAR and altered vasoconstriction in response to U46619l in a SGLT1/2 and EDHF 
dependent manner. 
Tissue microvesicles, tissular microparticles, endothelial dysfunction and senescence  
